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Abstract 
 
γ-aminobutyric acid type-A (GABAA) receptors are heteropentameric ligand-
gated chloride channels that mediate the majority of fast synaptic inhibition in 
the brain.  Emerging evidence indicates that their functional expression is 
subject to dynamic modulation by phosphorylation. However, the cell signaling 
molecules responsible for regulating GABAA receptor phosphorylation and thus 
the efficacy of neuronal inhibition remain to be identified. The β subunits are of 
particular interest in this context as their intracellular domains contain 
conserved serine residues (S409 in β1, S410 in β2 and S408/9 in β3), known 
substrates for a number of protein kinases, including PKA and PKC. In vitro 
binding experiments showed that phosphorylation and/or mutation of these 
residues confers a reduction in binding of GABAA receptor β subunits to the µ2 
adaptin of the clathrin adaptor protein (AP)-2 complex - a critical regulator of 
GABAA  receptor endocytosis  and surface number.  Consistent with this, 
coimmunoprecipitation of AP2-µ2 adaptin with endogenous GABAA receptor 
β3 subunits was significantly reduced in cultured neurons treated with a potent 
inhibitor of S408/9 dephosphorylation that was accompanied by an increase in 
the stability of GABAA receptor β3 subunits at the cell surface. 
 
Interestingly, recent studies have implicated PKA and PKC in the mediation of 
serotonergic modulation of GABAA receptor activity in the prefrontal cortex, 
suggesting that phosphorylation of GABAA receptor β subunits may underlie 
this regulation. To address this, a phospho-specific antibody directed against β3 
at S408/9 was developed. Immunoblotting with anti-pS408/9-β3 demonstrated a   5 
PKC-dependent increase in the phosphorylation state of GABAA receptor β3 
subunits following enhanced 5-hydroxytryptamine type-2 (5-HT2) receptor 
activation ex vivo. Moreover, in vivo biochemical and immunohistochemical 
studies revealed region-specific increases in GABAA  receptor  β3  subunit 
phosphorylation in mice dosed with the selective serotonin reuptake inhibitor 
(SSRI) fluoxetine (Prozac™), a commonly prescribed antidepressant. Together, 
the results presented herein suggest that the phospho-dependent increase in 
GABAA receptor functional expression may underlie the therapeutic action of 
SSRIs.    6 
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Introduction   23 
GABA is the major inhibitory neurotransmitter in the brain 
 
The  amino  acid  γ-aminobutyric acid (GABA) is the major inhibitory 
neurotransmitter in the adult mammalian central nervous system (CNS). GABA 
was first reported to be present in large quantities in the mammalian brain in 
1950 independently by both Awapara and Roberts (Awapara et al., 1950; 
Roberts and Frankel, 1950), who also demonstrated its synthesis from the 
excitatory neurotransmitter glutamate by glutamic acid decarboxylase (GAD) 
(Fig 1.1). It is now estimated that at least one third of all CNS neurons utilize 
GABA as their primary neurotransmitter, and that most of these GABAergic 
neurons are interneurons and therefore uniquely able to alter the excitability of 
local circuits within a given brain region (Bloom and Iverson, 1971). 
 
Interest in GABA as an inhibitory neurotransmitter was initiated by Bazemore 
and Florey, who demonstrated that GABA was the major component of an 
inhibitory factor (Factor I) isolated from mammalian brain that could mimic the 
effect of stimulating presynaptic inhibitory neurons at the crustacean stretch 
receptor and neuromuscular junction (Bazemore et al., 1957; Boistel and Fatt, 
1958; Florey and McLennan, 1959; Kuffler and Edwards, 1958). Taking 
advantage of the numeric simplicity of the crustacean nervous system, further 
work carried out by Kravitz and his collaborators provided unequivocal 
evidence for GABA as an inhibitory neurotransmitter in invertebrates (Kravitz 
et al., 1963; Otsuka et al., 1966). However, it proved considerably more difficult 
to firmly establish its role as a neurotransmitter in the vertebrate CNS. This was   24 
Adapted from C3 Neuropharmacology – UCL, 1998 
 
Figure 1.1:  GABA synthesis, uptake and metabolism.  GABA is synthesized in nerve 
terminals from the amino acid glutamate in a reaction catalyzed by glutamic acid decarboxylase 
(GAD), requiring pyridoxal phosphate (PLP) as a cofactor. The vesicular inhibitory amino acid 
transporter (VIAAT) then transports GABA into synaptic vesicles, where it is stored and 
released in a calcium-dependent manner upon depolarization of the pre-synaptic membrane. 
Following release into the synaptic cleft, the actions of GABA are terminated principally by its 
re-uptake into GABAergic presynaptic nerve terminals and/or surrounding glia by plasma 
membrane GABA transporters (GATs). GABA is then metabolized by GABA-transaminase 
(GABAT) which, like GAD, requires PLP as a cofactor. This transamination reaction breaks 
down GABA to  succinic  semialdehyde  and,  in  the  presence  of  α-ketoglutarate, the GABA 
precursor glutamate.  The enzyme succinic semialdehyde dehydrogenase (SSADH) rapidly 
converts succinic semialdehyde into succinic acid, which then enters the Krebs cycle.   25 
resolved when Krnjevic and Schwartz showed that exogenous application of 
GABA to cerebral cortical neurons results in membrane hyperpolarization with 
similar  reversal potentials to those  observed with the endogenous ligand 
(Krnjevic and Schwartz, 1967). There followed an exponential growth in 
research activities on GABA to define all the necessary criteria of a classical 
neurotransmitter and its overall role in the physiology of the brain. 
 
GABA acts on three major receptor subtypes 
 
GABA exerts its powerful inhibitory influence by acting on three distinct 
classes of GABA receptors based on their electrophysiological and 
pharmacological properties. Ionotropic GABAA and GABAC receptors are fast 
acting ligand-gated chloride channels, while metabotropic GABAB receptors are 
coupled indirectly via guanidine nucleotide-binding proteins (G proteins) to 
either calcium or potassium channels to produce slow and prolonged inhibitory 
responses.  
 
GABAA receptors 
 
The GABAA  receptor was the first to be identified and is responsible  for 
mediating the majority of fast synaptic (phasic) inhibition in the brain. It is 
activated by muscimol, a rigid analog of GABA isolated from the 
hallucinogenic mushroom Amantia muscaria and competitively blocked by the 
convulsant bicuculline. In addition, GABAA receptors are subject to allosteric   26 
modulation by a number of centrally active drugs, including benzodiazepines, 
barbiturates, neuroactive steroids, anesthetics and ethanol (reviewed in Sieghart 
et al., 2006).  
 
The classic GABAA receptor-mediated rapid hyperpolarization of the membrane 
potential is attributed to the direct activation of an integral ion channel and the 
resultant influx of chloride along its electrochemical gradient, with the 
concentration-response curve exhibiting positive cooperativity consistent with 
the presence of at least two agonist binding sites on the receptor complex 
(Baumann et al., 2003). In developing neurons,  GABAA  receptor activation 
results in chloride efflux and depolarization of the cell. GABA has thus been 
shown to act as an excitatory neurotransmitter at this stage  (Ben-Ari et al., 
1989; Zhang et al., 1991). This is largely due to the fact that there is a relatively 
high intracellular chloride concentration in immature neurons which decreases 
upon the functional expression of the potassium chloride cotransporter (KCC)-2 
as development proceeds, allowing GABA to become progressively inhibitory 
(Rivera et al., 1999). 
 
In the cerebellum, phasic and tonic modes of GABAA  receptor-mediated 
inhibition have been observed. This has been attributed to the presence of 
synaptic and extrasynaptic receptors, respectively (Brickley et al., 1996, 1999). 
Activation of GABAA  receptors located at synaptic sites, following brief 
exposure to high (millimolar) concentrations of GABA (released from 
presynaptic vesicles), transiently moves the membrane potential away from the   27 
spike threshold required for action potential generation and phasic inhibition of 
neuronal excitability. In contrast, low (submicromolar) concentrations of 
ambient GABA in the extracellular space can persistently activate spatially and 
temporally less restricted extrasynaptic receptors  to generate a basal tonic 
inhibitory state (reviewed in Farrant and Nusser 2005).  
 
GABAB receptors 
 
It has now become apparent that most classical neurotransmitters, including 
GABA, have both rapid and modulatory effects. GABA mediates slow synaptic 
inhibition by acting on heterodimeric G protein-coupled GABAB  receptors 
composed of R1 and R2 receptor subunits, which are widely expressed in the 
CNS and also in peripheral autonomic terminals (Bowery et al., 1987; Calver et 
al., 2000; Chu et al., 1990; Margeta-Mitrovic et al., 1999). 
 
GABA acting on presynaptically located GABAB  receptors inhibits 
neurotransmitter release,  including the release of GABA in the case of 
autoreceptors, by depressing calcium influx
 through voltage-dependent calcium 
channels (VDCCs). The activation of postsynaptic GABAB receptors triggers 
the opening of inwardly rectifying potassium (Kir)-3 channels and potassium 
efflux, resulting in a prolonged neuronal hyperpolarization that underlies the 
late phase of inhibitory postsynaptic currents (IPSCs). In addition to regulating 
ion channel function, GABAB  receptors can also inhibit adenylate cyclase 
activity and further decrease the cell’s conductance to calcium (for a detailed 
review of GABAB receptor function refer to Bettler and Tiao, 2006). GABAB   28 
receptors were first discovered in the early 1980s when Bowery and others 
(1981) demonstrated a slow bicuculline-insensitive GABA-mediated inhibition 
of evoked [
3H]-noradrenalin release in the rat heart. It is now well established 
that GABAB receptors are activated by baclofen, which is a lipophilic derivative 
of GABA, and blocked by saclofen, neither of which have any effect on 
chloride conductance in central neurons  (reviewed in Bonanno and Raiteri, 
1993). 
 
GABAC receptors 
 
GABAC receptors are the newly accepted member of the GABA receptor family 
and are expressed predominantly in retinal neurons (Feigenspan and Bormann, 
1994; Feigenspan et al., 1993; Polenzani et al., 1991). They are exclusively 
composed  of  ρ  subunits  that  are structurally related to the GABAA receptor 
subunits, and as such may be viewed as a variant within the GABAA receptor 
family (reviewed in Bormann et al., 2000).  
 
Although structurally homologous to the GABAA receptor, GABAC receptors 
are not blocked by bicuculline and do not recognize the characteristic GABAA 
receptor allosteric modulators.  Instead,  cis-4-aminocrotonic acid (CACA) a 
conformationally restricted analog of GABA is considered a selective GABAC 
receptor agonist (Johnston et al., 1975) and 1,2,5,6-tetrahydropyridine-4-yl 
methyl phosphinic acid (TPMA) a selective GABAC  receptor antagonist 
(Ragozzino et al., 1996. Moreover, the endogenous ligand GABA is about an 
order of magnitude more potent at GABAC  receptors, which deactivate and   29 
desensitize more slowly than the transiently activated GABAA receptors, and 
therefore exhibit a more sustained response to GABA (reviewed in Bormann 
and Feigenspan, 1995). It is these differences between GABAA and GABAC 
receptors that have led the argument for the distinction of these two classes of 
GABA receptors (reviewed in Bormann, 2000). 
 
Pharmacology of GABAA receptors 
 
The pharmacology of GABAA receptors is rich and a key target for a number of 
clinically relevant compounds including benzodiazepines, barbiturates, 
neuroactive steroids, certain classes of anesthetics, and ethanol. These allosteric 
compounds bind to discrete sites distinct from the agonist binding site to either 
positively or negatively modulate GABA-gated chloride conductance (reviewed 
in Sieghart et al., 2006).  
 
Benzodiazepines are a class of psychoactive drugs with varying anxiolytic, 
anticonvulsant, muscle relaxant, sedative, hypnotic, and amnestic properties. 
However, chronic use of these drugs results in tolerance and physical 
dependence limiting their clinical use. Classical benzodiazepine agonists, for 
instance diazepam (Valium™),  act by increasing the affinity of GABAA 
receptors for GABA and by increasing the frequency of channel opening in 
response to GABA binding. In contrast, inverse agonists, such as β-carboline-3-
carboxylate (β-CCE), decrease the frequency of channel opening and are highly 
anxiogenic and proconvulsant. Antagonists,  such as  flumazenil  (Anexate™),   30 
have no intrinsic activity but block the actions of both agonists and inverse 
agonists and are sometimes used to reverse the CNS depressant effects of 
benzodiazepine agonists in anesthesia and overdose. There has been 
considerable interest in the development of such partial agonists in the treatment 
of anxiety as bretazenil which has submaximal efficacy at the receptor and thus 
exhibits continued anxiolysis with reduced sedative and withdrawal side-effects 
(Sellers et al., 1992).  
 
Like the classical benzodiazepines, barbiturates  display a wide spectrum of 
effects from sedation to general anesthesia and are also effective as anxiolytics 
and anticonvulsants. However, barbiturates have now largely been replaced by 
benzodiazepines due to their increased addiction potential and risk of lethal 
overdose. Sedative barbiturates such as phenobarbitone (Luminal™)  or the 
intravenous general anesthetic thiopentone (Pentothal™) potentiate responses to 
GABA by increasing the mean channel open time, with little effect on opening 
frequency. In addition, at high (anesthetic) doses barbiturates can activate 
GABAA receptors directly and therefore also increase the maximal response, 
thus contributing to their toxicity (Twyman et a., 1989). 
 
Since the 1940s it has been recognized that the endogenous neuroactive steroids 
of the pregnane series such as  allopregnanolone and allotetrahydrodeoxy-
corticosterone (THDOC), have innate anxiolytic, anticonvulsant and sedative 
activity. These early studies led to the development of the general intravenous 
anesthetic Althesin™, which was withdrawn from human use due to rare but   31 
serious toxicity but is still used in veterinary medicine. The active component of 
this drug  -  alphaxolone  -  has been shown at low concentrations to 
stereoselectively facilitate GABA-mediated inhibition  by increasing both the 
frequency and duration of channel opening. However, at higher concentrations 
alphaxolone has also been shown to directly activate GABAA receptors in a 
manner inconsistent with competition for a common binding site with the 
barbiturates (Clarke et al., 1973).  More  recently, another synthetic steroid - 
ganaxolone  -  has been developed and is currently in clinical trials for the 
treatment of epilepsy. This drug has less sedative effects than the anesthetic 
steroids  depicted above, but is  a potent anticonvulsant  that  may have some 
advantages over older antiepileptics, mainly less development of tolerance with 
long term treatment (reviewed in Nohria and Giller, 2007).  In addition to 
anesthetic steroids and barbiturates, a number of other anesthetic compounds 
belonging to different chemical classes,  such as the inhalation anesthetics 
isoflurane  (Aerrane™)  and halothane  (Fluthane™)  and the intravenous 
anesthetics propofol (Rapinovet™) and etomidate (Amidate™), are also known 
to potentiate GABA-gated chloride conductance at pharmacologically relevant 
concentrations. However, at higher concentrations they too can directly open 
GABAA receptor-associated chloride channels (Banks et al., 1999; Kitamura et 
al., 2004).  Although the majority of studies have focused on the GABAA 
receptor, it is evident that some anesthetics, such as ketamine (Anaket-V™) and 
nitrous oxide  (‘laughing gas’), do  not produce their effects by directly 
interacting with the receptor complex (reviewed in Hirota, 2006). 
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Similar to other GABAA receptor modulators discussed above, ethanol exhibits 
an array of CNS depressant effects (reviewed in Deitrich et al., 1989). 
Prolonged exposure to and subsequent withdrawal of ethanol are associated 
with marked changes in GABAA  receptor subunit gene expression and 
subsequently the function and pharmacology of the assembled channel 
complexes, which have been implicated in alcohol withdrawal syndrome (Sanna 
et al., 2003).  
 
In addition, GABAA receptors are inhibited by a number of potent convulsants 
including t-butylbicyclophosphorothioate (TBPS) and picrotoxin, both of which 
noncompetitively block the receptors by binding to a site within the ion channel 
pore,  effectively obstructing any ions from moving through the pore  and 
stabilizing the receptor complex in an agonist-bound desensitized state (Jursky 
et al., 2000; Newland and Cull-Candy, 1992; Zhang et al., 1994). Finally, 
GABAA receptor function is also subject to regulation by divalent ions such as 
zinc (Smart et al., 2004; Smart et al., 1992) and changes in pH (Krishek et al., 
1996). 
 
Structure and assembly of GABAA receptors 
 
GABAA  (and GABAC) receptors belong to the superfamily of cysteine-loop 
ligand-gated ion channels that comprises nicotinic acetylcholine (nACh) 
receptors, strychnine-sensitive glycine receptors, and 5-hydroxytryptamine 
type-3 (5-HT3) receptors (reviewed in Connolly and Wafford, 2004). Members   33 
of  this receptor family are heteropentameric glycoproteins composed of 
homologous subunits that specifically recognize one another and assemble 
around an intrinsic ion pore (Unwin, 1993), which in the case of the GABAA 
receptor is chloride selective (reviewed in Sieghart et a., 2006).  
 
In the mid 1980s collaborative work carried out by the groups of Barnard and 
Seeburg led to the cloning of the first two GABAA receptor subunits known, α 
and  β  (Schofield et al., 1987), following their successful purification from 
bovine brain earlier that decade (Sigel et al., 1982). Analysis of the deduced 
amino  acid  sequences  of  the  α  and  β  subunit  cDNAs  isolated  by  these 
investigators indicated that each subunit, approximately 50-60  kDa in size, 
consists of a large extracellular ligand binding N-terminal region and a short 
barely extruding C-terminus separated by four highly conserved hydrophobic 
transmembrane (TM)1-4 α-helices. In addition, a major cytoplasmic loop lies 
between TM3 and TM4 that is the most divergent part of the sequence among 
the subfamily (Fig 1.2). This intracellular domain (ICD) mediates the 
interaction with cytosolic proteins and is subject to a number of post-
translational modifications. Coexpression of the α and β subunits in Xenopus 
oocytes  resulted in the assembly of bicuculline-sensitive GABA-activated 
chloride channels that, however, lacked the characteristic benzodiazepine 
potentiation observed with native GABAA receptors (Angelotti and Macdonald, 
1993). A novel GABAA receptor subunit (γ) that when coexpressed with α and 
β subunits conferred benzodiazepine sensitivity on the assembled receptor was 
then identified (Pritchett et al., 1989).  It is now firmly established that the  34 
Adapted from Jacob et al., 2008 
 
Figure 1.2:  GABAA  receptor structure.  (A)  Transmembrane topology of the  GABAA 
receptor. Each receptor subunit is composed of a large extracellular ligand binding N-terminal 
region  that is also the site of action of various drugs  followed by four hydrophobic 
transmembrane  (TM)1-4  α-helices  and a short,  barely extruding C-terminus.  A  large 
intracellular domain (ICD) between TM3 and TM4 mediates the majority of protein-protein 
interactions and is also subject to a number of post-translational modifications. (B) Transverse 
view of the assembly of GABAA receptor subunits to form an ion channel. TM2 faces the lumen 
of the channel ion pore and TM4 is anchored in the lipid membrane. TM1 and TM3 interact 
with the neighboring subunits, respectively.   35 
GABA binding site  is  located at the  interface  between  α  and  β  subunits 
(Baumann et al., 2003), whereas that of benzodiazepines lies between the α and 
γ subunits (Sigel and Buhr, 1997).  
 
Nineteen GABAA receptor subunits have been cloned and sequenced from the 
mammalian brain thus far. These have been divided into eight classes on the 
basis of sequence identity (reviewed in Whiting et al., 1999): α(1-6), β(1-3), 
γ(1-3),  δ,  ε,  π,  θ,  and  ρ(1-3). Subunit isoforms within a single class share 
approximately 70% sequence identity but between classes this falls to 30-40%. 
Moreover, alternatively spliced variants of several of these subunits have been 
reported generating further subunit diversity and the potential for extensive 
molecular heterogeneity (reviewed in Sieghart et al., 1999). For example, the γ2 
subunit exists in short (γ2S) and long (γ2L) forms, which differ in an eight 
amino acid insert in the ICD of the γ2L subunit (Whiting et al., 1990; Kofuji et 
al., 1991). Despite the plethora of GABAA receptor subunit isoforms, due to the 
selective oligomerization mediated by receptor
 assembly only a limited number 
of combinations are expressed in vivo (reviewed in Sieghart and Sperk, 2002; 
Sieghart et al., 1999). The majority of GABAA receptor subtypes in the brain 
are  composed  of  α1β2γ2,  followed  by  α2β3γ2  and  α3β3γ2, with a likely 
stoichiometry of 2α.2β.γ, similar to that found for of nACh receptors (Chang et 
al., 1996; Farar et al., 1999; Knight et al., 2000; Tretter et al., 1997). To a lesser 
extent, δ, ε, π subunits replace the γ subunit to form benzodiazepine-insensitive 
receptor  subtypes,  whereas  the  θ  subunit  has  been  shown  to  replace  the  β 
subunit. Conversely, ρ subunits rarely coassemble with other GABAA receptor   36 
subunits, but instead homo- as well as heterooligomerize with other ρ subunits 
to form the GABAC receptor (reviewed in Bormann et al., 2000).  
 
To date, no receptor belonging to the superfamily of ligand-gated ion channels 
has  been  characterized structurally by X-ray crystallography.  However, 
comparative modeling of the  GABAA  receptor  based to  the 4 Å resolution
 
model of the Torpedo nACh receptor has for the first time provided an insight 
into the 3D organization of this ligand-gated ion channel (Ernst et al., 2005). 
The extracellular domain of each receptor subunit comprises a variable N-
terminal  domain  and  two  β-folded  sheets that form a twisted sandwich 
connected by a signature disulphide bridge.  Confirming existing data, the 
GABA-binding sites are located in solvent-accessible pockets at the two β+α- 
subunit interfaces and that of benzodiazepines at the α+γ- interface (Ernst et al., 
2003).  The  TM  domain  of the receptor is made up of four loosely-packed 
helical bundles resulting in a considerable amount of solvent-accessible space 
within subunits and at the subunit interfaces.  The  intersubunit  pockets have 
been proposed to form a continuous groove with their extracellular counterparts, 
suggesting that they may play a role in the conformational mobility of the 
receptor  but may also provide putative drug-binding sites. The  intrasubunit 
pockets contain a number of amino acid residues that have been shown to be of 
key importance in the binding and/or efficacy of a number of modulatory drugs. 
For example, a pocket within the α1 subunit, defined by the presence of S270 in 
TM2 and A291 in TM3, is thought to correspond to the site of action of volatile 
anesthetics (Nishikawa et al., 2002). Similarly, the presence of a homologous   37 
serine residue (S265) in the intrasubunit pocket of β1, which is replaced by an 
aspartic residue in the β2 and β3 subunit isoforms, is believed to account for the 
subtype-selectivity of etomidate and other related substances  (Belelli et al., 
1997). Future experiments, leading to the improvement in the accuracy of the 
models, will not only continue to provide a new perspective on existing data, 
but also pave the way for structure-based drug design. 
  
GABAA receptor subunit expression within the brain 
 
In addition to molecular determination of GABAA receptor
 assembly, subunit 
composition
 is further limited by the spatial and temporal pattern of subunit 
expression.  In situ  hybridization (Laurie et al., 1992; Persohn et al., 1992; 
Wisden et al., 1992) and immunohistochemical (Fritschy et al., 1992; Pirker et 
al., 2000; Sperk et al., 1997) studies have demonstrated that each one of the 
subunits has a distinct regional and cellular distribution within the brain. 
Moreover, different subunits and/or subunit combinations further dictate the 
subcellular localization of these ligand-gated chloride channels and determine 
their biophysical and pharmacological properties. Detailed knowledge of the 
molecular composition and the exact anatomical expression of different 
GABAA  receptor subtypes is  therefore  crucial in understanding the 
physiological actions of GABA within the brain and for developing potentially 
clinically useful subtype-selective drugs that lack unwanted side-effects. 
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Regional and cellular distribution 
 
The α1, β2, β3 and γ2 subunits indeed show the most prevalent expression and 
have been detected in numerous cell types throughout the brain (Laurie et al., 
1992; Wisden et al., 1992; Pirker et al., 2000). The α2 and α3 subunits, like α1, 
are found in most brain regions, albeit at lower levels. Interestingly, α2 and α3 
subunits are highly expressed in neonates compared to α1, suggesting that the 
level of expression of these subunits is developmentally regulated (Laurie et al., 
1992b). The α3 subunit is the predominant receptor subtype expressed in the 
raphé nucleus, where only a small population of serotonergic neurons coexpress 
α1. The α3 subunit is also expressed in dopaminergic and noradrenergic neurons 
in the brainstem and shows an overlapping distribution with the θ  and  ε 
subunits, suggesting that novel GABAA  receptors subtypes may regulate 
neuromodulatory and neruoendocrine systems in the brain (Moragues et al., 
2002). In contrast, both α1 and α3 subunit immunoreactivities are present in 
GAD-positive neurons (Gao et al., 1993). The α4 subunit is restricted to the 
thalamus, striatum and molecular layer of the dentate gyrus and is the least 
abundant α subunit (Pirker et al., 2000; Wisden et al., 1992). The α5 subunit is 
enriched in the Cornu Ammonis (CA)1  region of the hippocampus, cerebral 
cortex and olfactory bulb, whereas the α6 subunit is found almost exclusively in 
the granular layer of the cerebellum (Laurie et al., 1992a; Pirker et al., 2000). 
 
Despite a wide distribution of all three β subunits - notably the cerebral cortex, 
β1 is expressed at much lower levels than the β2 and β3 subunits (Pirker et al., 
2000). In subcortical areas and the cerebellum, a higher level of expression of   39 
one β subunit comes at the expense of another. For example, the β2 subunit is 
highly expressed in the thalamus compared to β1 and β3 subunits (Wisden et al., 
1992; Pirker et al., 2000), whereas the β3 subunit is highly expressed in the 
striatum where the β2 subunit is less abundant. In the hippocampal formation, 
β1 and β3 subunit expression is higher than that of β2 (Wisden et al., 1992) and, 
in this region, β1 and β3 subunits are found mainly in the dendrites of pyramidal 
neurons, whereas the β2 subunit is expressed primarily in interneurons (Pirker 
et al., 2000). In addition, the β1 subunit is more concentrated in the CA2 than 
the CA1 or CA3 subfields of the hippocampus, whereas the reverse is true for 
β3 (Pirker et al., 2000). In the cerebellum, β2 and β3 subunits are enriched in 
the granular layer and the β1 subunit the molecular layer (Pirker et al., 2000).  
 
The γ1 subunit is restricted to very few brain regions, essentially the central and 
medial amygdaloid nuclei, in pallidal areas, the substantia nigra pars reticulata 
and the inferior olive, and may replace the γ2 subunit in these areas (Pirker et 
al.,  2000).  In  contrast,  the  γ3  subunit  is  distributed  diffusely  at low 
concentrations throughout the brain and constitutes a very limited number of 
receptors  (Pirker et al., 2000).  While the levels of the γ2 subunit remain 
relatively constant during ontogeny, that of the γ1 and γ3 subunits decreases 
with development (Fritschy et al., 1994). The  distribution  of  the  δ  subunit 
parallels that of the α4 and α6 subunits and has been shown to replace the γ2 
subunit in GABAA receptors containing the α4 or α6 subunits in the thalamus 
and granular layer of the cerebellum, respectively (Laurie et al., 1992a; Wisden 
et al., 1992; Pirker et al., 2000). The ε, π, θ are the least abundant GABAA   40 
receptor subunits in the brain, and currently little is known about the functional 
relevance of their expression. 
 
Subcellular localization 
 
Immunofluorescence and immunogold microscopy studies have revealed that 
synaptic and extrasynaptic receptors differ in their subunit composition. For 
example, in the cerebellum the γ2 subunit has been shown to be a component of 
all postsynaptic GABAA  receptors,  whereas  the  δ  subunit  is  found  almost 
exclusively at extrasynaptic sites (Nusser et al., 1998b). The importance of the 
γ2 subunit in the postsynaptic targeting of GABAA receptors is demonstrated by 
the profound reduction in the clustering of both GABAA  receptors and the 
inhibitory synaptic marker gephyrin seen in γ2 subunit knockout mice (Essrich 
et al., 1998). Hence, GABAA receptors incorporating a γ2 subunit together with 
α1-3 subunits (α1-3β2/3γ2) are the predominant receptor subtypes responsible 
for mediating phasic inhibition. It is important to note however that these 
receptor subtypes are also abundant at perisynaptic and extrasynaptic sites, 
which is consistent with recent evidence for the dynamic mobility and rapid 
exchange of γ2 subunit-containing receptors between extrasynaptic and synaptic 
receptor pools (Jacob et al., 2005; Thomas et al., 2005). 
 
The  α1  subunit  exhibits  punctate  and  diffuse  staining  in  the  hippocampus 
indicating both a synaptic and extrasynaptic localization, which can in part be 
explained by its association with γ2 and δ subunits, respectively (Brunig et al., 
2002). α1 subunit-containing GABAA receptor clusters are selectively enriched   41 
on somatic membrane sites at GABAergic terminals that originate from 
parvalbumin-positive basket cells (Thomson et al., 2000; Klausberger et al., 
2002). In contrast, the extensively  clustered  α2  subunit-containing GABAA 
receptors are strategically positioned at synapses on the axon initial segment 
(AIS) of pyramidal neurons that are innervated specifically by parvalbumin-
positive chandelier cells  (Brunig et al., 2002).  They are also found at axo-
somatic synapses at GABAergic terminals, which originate form 
cholecystokinin-positive basket  cells (Brunig et al., 2002).  The  α3  subunit 
appears to be differentially targeted depending on its cellular distribution within 
the hippocampus. In pyramidal neurons it is concentrated at synaptic sites, but 
in a subset of hippocampal cells characterized by a round cell body and 
numerous short dendrites it displays a diffuse pattern of expression and fails to 
colocalize with gephyrin (Brunig et al., 2002). The α5 subunit is unique in that, 
despite its coassembly with a γ2 subunit (α5β3γ2), it is enriched at extrasynaptic 
sites (Brunig et al., 2002). In accordance with this finding, deletion of the α5 
subunit eliminates tonic conductance in cultured hippocampal neurons 
(Caraiscos et al., 2004). However, there is a pool of α5 subunit-containing 
GABAA receptors that concentrates at GABAergic synapses on CA1 pyramidal 
cell dendrites (Serwanski et al., 2006). In a recent study, diazepam-sensitive 
IPSCs  elicited by dendrite preferring interneurons in the rat neocortex was 
blocked by the α5  subtype-selective inverse agonist (α5IA), suggesting that 
α5βγ2 receptor subtypes may also play also play a role in phasic inhibition (Ali 
and Thomson, 2008). As depicted earlier, α4 and α6 subunits form assembled 
channel  complexes  with  δ  subunits  (α4βδ  and  α6βδ)  that  are  exclusively   42 
extrasynaptic, accounting for tonic conductance in the thalamus and cerebellum, 
respectively (Nusser et al., 1998b). On the other hand, the majority of phasic 
signaling  in  the  cerebellum  is  largely  due  to  synaptic  α6  subunit-containing 
receptors of the α6β2γ2 combination (Nusser et al., 1998b). 
 
Functional significance of molecular heterogeneity 
 
While the exact subcellular localization of different GABAA receptor subtypes 
undoubtedly contributes to their participation in phasic and tonic forms of 
signaling, this distinction alone is not sufficient to account for their differential 
activation. Subunit composition is a major determinant of the binding and 
gating properties of the ion channels, and hence the magnitude of the response 
following exposure to ligand. Studies using recombinant GABAA  receptors 
have  revealed  that sensitivity  to  GABA  is  defined  by  the  type  of  α  subunit 
present, where extrasynaptic α6β3δ and α4β3δ subunit compositions display the 
highest affinities for GABA and synaptic α3β3γ2 subtypes the lowest (Bohme et 
al., 2004). For both αβγ and αβδ assemblies, the identity of the α subunit also 
affects the rates of activation, deactivation and desensitization (Bianchi et al., 
2002;  Caraiscos et al., 2004; Gingrich et al., 1995; Lavoie et al., 1997; 
McClellan and Twyman, 1999; Tia et al., 1996). Conversely, in αβ3γ2 subunit-
containing  receptors  replacing  the  γ2  subunit  with  a  δ  subunit  results  in a 
dramatic reduction in single channel conductance independent of the type of α 
subunit present (Fisher and Macdonald, 1995), which supports the notion that 
GABA has a high affinity but low efficacy at δ subunit-containing extrasynaptic   43 
receptors. The presence of a γ2 or δ subunit also influences channel kinetics; 
importantly αβδ receptors desensitize more slowly and less extensively than αβγ 
receptors (Bianchi and Macdonald, 2002; Haas and Macdonald, 1999; Saxena 
and Macdonald, 1996). Together the distinct biophysical properties of γ and δ 
subunit-containing receptors are wholly consistent with the involvement of 
these receptor subtypes in phasic and tonic signaling, respectively.  
 
Differences in subunit composition between synaptic and extrasynaptic 
receptors are reflected in a differential modulation of phasic and tonic signaling 
by a number of compounds of therapeutic importance. The most frequently 
cited example of this is the role of the α subunit in defining receptor affinity for 
benzodiazepines. GABAA receptors incorporating either an α4 or α6 subunit 
infers insensitivity to benzodiazepines (Benson et al., 1998), as does elimination 
or substitution of the γ2 subunit. This difference can be attributed solely to the 
presence of a conserved arginine residue in α4 and α6 subunits, which in α1-3 
and α5 subunits is histidine (Wieland et al., 1992). Thus benzodiazepine site 
ligands selective for α1-3 subunits largely influence phasic signaling, whereas 
those  selective  for  α5  subunits  are  capable of primarily modulating tonic 
conductance. The diverse CNS depressant effects of benzodiazepines have been 
attributed to specific α subunit types of GABAA receptors (reviewed in Rudolph 
and Möhler, 2004). A combined molecular genetic and pharmacologic approach 
has  revealed  that  α1  subunit-containing receptors mediate sedative, amnestic 
and,  in part,  the anticonvulsant actions of diazepam, whereas α2  subunits 
contribute to its anxiolytic and muscle-relaxant effects. Strong pharmacological   44 
evidence for the involvement of the α3 subunit in anxiety comes from a study 
by Atack and colleagues (2005) showing that the α3 subtype-selective inverse 
agonist (α3IA) induces an anxiogenic response in rats. The α5 subunit has been 
implicated in learning and memory following the observation that a single point 
mutation (H105R), which prevents the interaction of this receptor subtype with 
diazepam,  abolishes its memory impairing effects  (Crestani et al.,  2002). 
Moreover, the development of tolerance to the sedative actions of chronic 
diazepam is associated with a downregulation of α5 subunit-containing GABAA 
receptors, to which α5-H105R mice are resistant (Rijnsoever et al., 2004).  
 
Following insights into GABAA  receptor subtypes mediating the effects of 
benzodiazepines,  subtype-selective drugs sharing with the classical 
benzodiazepines the overall high tolerability but therapeutic effects that are 
more selective than the classical benzodiazepines,  have been  developed 
(reviewed in Whiting, 2006). For example, zolpidem (Ambien®), which is a 
commonly prescribed sleep-aid, has a higher affinity for α1 subunit-containing 
GABAA receptors (Depoortere et al., 1986; Pritchet and Seeburg, 1990). To 
date, no compounds with selective binding affinity for α2 or α3 subunit-
containing receptors have been described.  L-838417, whilst not binding 
selective, exhibits significant efficacy selectivity for α2,  α3 and α5 subunit-
containing receptors over those of the α1 subtype (McKernan et al., 2000). In 
animal behavioral models, L-838417 was found to be an effective anxiolytic 
agent with a 30-fold separation over doses needed to elicit a sedative effect and 
also  exhibited  a reduced abuse potential compared with both classical   45 
nonselective benzodiazepines and zolpidem (McKernan et al., 2000; Rowlett et 
al., 2005). Interestingly, the non-sedative anxiolytic TP-003 has significant 
efficacy only at α3 subunit-containing receptors, further supporting a role for 
this receptor subtype in mediating the anxiolytic response to benzodiazepines, 
(Dias et al., 2005). SL-651498, which is a full agonist at α2 and α3 subunit-
containing receptors and a partial agonist at α1 and α5 subunit-containing 
receptors,  is currently under development as a non-sedative anxiolytic for 
humans. Preliminary clinical trails with SL-651498 suggest similar efficacy to 
classical benzodiazepines as an anxiolytic, but with little or no sedation or 
impairment of motor skills, memory or cognitive function (de Haas et al., 2009). 
The α5 subtype-selective inverse agonist (α5IA) has equal binding affinity for 
α1, α2, α3 and α5 subtypes, but shows much higher efficacy at α5 subunit-
containing receptors. It acts either as a weak partial agonist or inverse agonist at 
the other subtypes, with its partial agonist effect at α2 likely to be responsible 
for the lack of anxiogenic effects produced by this drug when compared to older 
α5 subtype-preferring inverse agonists such as L-655708 (Atack, 2009; Dawson 
et al., 2006; Navarro et al., 2002). Whether or not such a compound has efficacy 
in conditions associated with cognitive deficits, such as attention-deficit 
hyperactivity disorder, Alzheimer's disease or schizophrenia remains to be 
determined. 
 
The diverse functions of GABA in the CNS are matched not just by the 
heterogeneity of GABAA  receptors but also by the complex trafficking and 
clustering mechanisms that generate and maintain surface receptor populations   46 
accessible to the  transmitter at inhibitory postsynaptic specializations or 
extrasynaptic sites, depending on their subunit composition. The regulation of 
these mechanisms by GABAA receptor associated proteins is discussed below 
(summarized in Table 1.1). 
 
Membrane trafficking of GABAA receptors 
 
GABAA receptors are not static entities on the neuronal cell surface but are 
believed to cycle continuously between the plasma membrane and intracellular 
compartments (reviewed in Arancibia-Carcamo and Kittler 2009). The relative 
rates of receptor exo-  and endocytosis are therefore key determinants in 
controlling the size of the postsynaptic pool accessible to GABA and 
GABAergic compounds and thus the strength of synaptic inhibition. 
Importantly, GABAA receptors have recently been reported to be inserted into 
and removed from the plasma membrane exclusively at extrasynaptic sites 
(Bogdanov et al., 2006; Thomas et al., 2005), highlighting the importance of 
lateral diffusion for their postsynaptic specialization. 
 
Exocytosis of GABAA receptors to the plasma membrane 
 
GABAA receptors can be delivered to the cell surface either as newly assembled 
channel complexes via a de novo secretory pathway, or reinserted following 
internalization. The oligomerization of GABAA receptor subunits into channel 
complexes is believed to occur in the endoplasmic reticulum (ER) and evidence   47 
Table 1.1:  GABAA receptor associated proteins 
 
Protein  Subcellular  
Localization 
Subunit 
specificity 
Proposed function 
GABARAP  Golgi  γ  Facilitates exocytosis 
PRIP1/2  Synapses  β  Enhances cell surface stability 
by inhibiting PP1α mediated 
dephosphorylation 
PLIC1  Intracellular 
compartments 
α/β  Facilitates exocytosis by 
inhibiting proteasome-dependent 
degradation 
BIG2  Intracellular 
compartments 
β  Promotes ER exit and structural 
integrity of recycling  
endosomes 
AP2  Clathrin-coated 
pits 
β/γ  Regulates clathrin-mediated 
endocytosis 
HAP1  Endosomes  β  Regulates post-endocytic sorting 
by inhibiting lysozomal 
degradation 
GODZ  Golgi  γ  Palmitoylation 
Gephyrin  Synapses  α1  Facilitates clustering/scaffolding 
at synaptic sites 
Radixin  Extrasynaptic 
sites 
α5  Facilitates clustering at 
extrasynaptic sites 
GRIF1  Intracellular 
compartments 
β2  Unknown 
gC1qR  Intracellular 
compartments 
β3  Unknown 
Adapted from Arancibia-Carcamo and Moss, 2006   48 
suggests that this assembly process plays a critical role  in determining the 
diversity of receptor subtypes expressed on the neuronal plasma membrane. 
Proteins cannot exit the ER until they have achieved their correctly folded 
conformation, and misfolded or unassembled proteins are retrotranslocated from 
this organelle for degradation in the proteasome, restricting the number of 
subunit combinations that can access the cell surface (reviewed in Kittler et al., 
2002).  Following correct  assembly, GABAA  receptors are trafficked to the 
Golgi apparatus and segregated into vesicles for transport to and insertion into 
the plasma membrane facilitated by a number of receptor associated proteins. 
 
Yeast two-hybrid screens using the γ2 subunit ICD as bait isolated the first 
known GABAA receptor associated protein (GABARAP) (Wang et al., 1999), a 
17  kDa cytosolic protein belonging to the family of membrane associated 
proteins (MAPs)  involved in membrane  trafficking, including the estrogen-
induced protein first isolated in guinea-pig endometrial cells (GEC)-1  (or 
GABRAP like-1), Golgi-associated transport enhancer of 16 kDa (GATE-16, or 
GABARAP  like-2), Apg8L and light chain  (LC)-3  subunits of MAP1. 
Interestingly, GABARAP knockout mice do not show differences in punctate 
staining of γ2  subunit-containing GABAA  receptors and lack an overt 
behavioral phenotype (O’Sullivan et al., 2005), suggesting that GABARAP may 
be functionally redundant. Nevertheless, the notion that GABARAP is involved 
in the trafficking of GABAA receptors to the plasma membrane is supported by 
the finding that overexpression of GABARAP in heterologous expression 
systems and in cultured hippocampal neurons results in an increase in the cell   49 
surface expression of γ2 subunit-containing GABAA receptors (Leil et al, 2004). 
In  Xenopus oocytes expressing α1β2γ2 subunit-containing GABAA receptors 
this was accompanied by an increase in GABAA receptor-mediated synaptic 
inhibition, an effect requiring the γ2 subunit- and microtubule-binding motifs as 
well as intact polymerized microtubules (Chen et al., 2005). More recently it 
was demonstrated that GABARAP-mediated exocytosis of GABAA receptors is 
necessary for potentiation of inhibitory transmission by NMDA receptor 
activation, suggesting that GABARAP might have a role in the regulated 
delivery of GABAA receptors to the plasma membrane after activity rather than 
in the maintenance of basal surface receptor levels (Marsden et al., 2007). 
 
Evidence in support of a function of GABARAP as a trafficking factor includes 
the identification of phospholipase C (PLC)-related catalytically inactive protein 
(PRIP)-1, a 130 kDa protein that is believed to competitively inhibit the binding 
of the γ2 subunit of GABAA receptors to GABARAP (Kanematsu et al., 2002). 
PRIP1 knockout mice show impairments in GABAA receptor modulation by 
benzodiazepines and zinc-sensitivity, indicating reduced activation of γ2 
subunit-containing receptors (Kanematsu et al., 2002). These findings suggested 
that PRIP1 might play a role in the regulation of GABAA receptor trafficking by 
GABARAP, ensuring that only mature αβγ receptor complexes are delivered to 
the plasma membrane. In addition, PRIP1 has been shown to directly bind to the 
ICD of GABAA receptor β1-3 subunits, serving as an adaptor protein for the 
protein phosphatase (PP)-1α, and as such has been implicated in the phospho-
dependent modulation of GABAA receptor functional expression (Terunuma et   50 
al., 2004). Recently, a second PRIP isoform (PRIP2) has
 been identified that, 
like PRIP1, binds both GABARAP and
 PP1α, suggesting a central role for all 
PRIP isoforms in modulating
 GABAA receptor functional expression (Uji et al., 
2002). 
 
GABAA receptors also interact with the protein that links the integrin-associated 
protein with the cytoskeleton  (Plic)-1. Plic1  is  a  67 kDa protein  with a 
ubiquitin-like (UBL) N-terminal domain and a ubiquitin-associated (UBA) C-
terminal domain (Kleijnen et al., 2000). It is able to bind ubiquitin ligases and 
components of the proteasome and as such is thought to interfere with ubiquitin-
dependent proteolysis of proteins (Kleijnen et al., 2000). Yeast two-hybrid 
screens and glutathione S-transferase (GST) affinity purification assays have 
shown that Plic1 interacts with the ICD of α1-3,6 and β1-3 (but not γ2 or δ) 
subunits of GABAA  receptors  (Bedford et al., 2001), indicating that Plic-1 
function might be relevant for the majority of receptor subtypes expressed in the 
brain. This interaction has been demonstrated to be of significance in mediating 
the  functional expression of GABAA  receptors  in  human embryonic kidney 
(HEK-293) cells and in hippocampal slices as revealed using dominant negative 
peptides (Bedford et al., 2001).  In a recent study by Saliba and colleagues 
(2008), the authors showed that Plic1 increases the accumulation of GABAA 
receptor β3 subunits on the cell surface in a manner independent of their rates of 
internalization. These findings suggested that Plic1 selectively modulates the 
secretory pathway. In accordance with this, Plic1 was found to significantly 
increase the half-life of polyubiquitinated GABAA receptor β3 subunits in the   51 
ER and facilitate their insertion into the plasma membrane (Saliba et al., 2008). 
By increasing the resident times of unassembled subunits in the ER, Plic1 may 
also increase subunit maturation and production of heteromeric receptors. Plic1 
regulation of the ubiquitin-dependent proteasomal degradation of GABAA 
receptors may thus provide a dynamic mechanism for regulating the efficacy of 
inhibitory synaptic transmission. 
 
The 190 kDa brefeldin A-inhibited guanine nucleotide exchange factor (BIG)-2 
was also identified as a GABAA receptor β subunit interacting protein in a yeast 
two-hybrid screen (Charych et al., 2004a). BIG2 is concentrated mainly in the 
trans-Golgi network but is also found in vesicle-like structures along dendrites 
and at the postsynaptic plasma membrane (Charych et al., 2004). Interestingly, 
coexpression of BIG2 with the GABAA  receptor  β3 subunit results in an 
increase in β3 exit from the ER, suggesting that BIG2 is involved in the post-
Golgi vesicular trafficking of GABAA receptors (Charych et al., 2004). It is 
currently proposed that BIG2 may  play a role in the transport of newly 
assembled GABAA receptors to the postsynaptic plasma membrane and also be 
involved in receptor recycling (Shen et al., 2006; Shin et al., 2004).  
 
Other GABAA receptor associated proteins implicated in the forward trafficking 
of GABAA receptors include the GABAA receptor interacting factor (GRIF)-1 
(Beck et al., 2002) and the multifunctional protein gC1qR  (Schaerer et al., 
2001). However, their functional significance remains unclear. 
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Endocytosis of GABAA receptors from the plasma membrane 
 
GABAA  receptors have been shown to be localized in clathrin-coated pits, 
suggesting that they undergo clathrin-mediated endocytosis (Fig 1.3), a process 
that is further dependent on dynamin for endocytic vesicle formation. The 
clathrin adaptor protein (AP)-2 is a central component in the formation of these 
vesicles, forging a link between membrane proteins and clathrin, which forms 
the outer layer of the coat. AP2 is a heterotetrameric complex composed of two 
large (~100 kDa) α and β2 subunits, a medium (50 kDa) µ2 subunit, and a small 
(19 kDa) σ2 subunit, commonly  referred to as adaptins.  The  α  adaptin  is 
responsible  for targeting  the  protein to  the  plasma  membrane,  where the  β2 
adaptin interacts with clathrin to trigger clathrin assembly, forming coated pits. 
This in turn leads to the activation of µ2 adaptin phosphorylation, inducing a 
conformational change in the subunit that allows the complex to directly bind to 
endocytic motifs in cell surface receptors, clustering the protein cargo into the 
assembling coated pit. Cargo is bound by the β2 and µ2 adaptins that mostly 
recognize a dileucine motif or the canonical tyrosine based YXXØ motif (where 
X denotes any amino acid and Ø a bulky hydrophobic residue) (Clague, 1998; 
Le Borgne and Hoflack, 1998). The σ2 adaptin is responsible for stabilizing the 
complex at the core by mediating subunit interactions. The AP2 complex also 
interacts with several accessory proteins that form essential components of the 
endocytic machinery (reviewed in Slepnev and De Camilli, 2000). 
 
GABAA receptors are intimately associated with AP2 in the brain through a 
direct binding of the β1-3 and γ2 GABAA  receptor subunits (Kittler et al.,  53 
Adapted from Jacob et al., 2008 
 
Figure 1.3:  Clathrin-mediated endocytosis. The receptors cluster in specialized sites at the 
plasma membrane known as clathrin-coated pits, which invaginate  and pinch off to form 
clathrin-coated vesicles (CCVs), a process that is dependent on dynamin. The clathrin adaptor 
protein (AP)-2 is a central component in the formation of these vesicles, forging a link between 
membrane proteins and clathrin which forms the outer layer of the coat.  The vesicles 
subsequently lose their coat and fuse together to form an early endosome. Internalized receptors 
are then either subject to rapid recycling or are targeted for lysozomal degradation, an endocytic 
sorting decision that is regulated by the Huntingtin-associated protein (HAP)-1.   54 
2000). In the GABAA receptor β2 subunit a dileucine AP2-β2 adaptin-binding 
motif (L
343L
344) has been identified. This motif is important for clathrin-
mediated endocytosis in HEK-293 cells and in cortical slices (Herring et al., 
2003, 2005). It is also present in the ICDs of receptor β1 and β3 subunits, but 
evidence suggests that it is not involved in the interaction of these subunits with 
the AP2 complex (Kittler et al., 2005). In addition, an atypical AP2-binding 
motif conserved within the ICD of all GABAA receptor β subunit isoforms has 
been identified (KTHLRRRSSQLK in the β3 subunit) (Kittler et al., 2005). This 
motif, which is enriched in lysine and arginine residues, also incorporates the 
major sites of phosphorylation for PKA and PKC within this class of receptor 
subunits:  S409  in  β1,  S410  in  β2  and  S408/9  in  β3  (Moss  et  al.,  1992).  A 
peptide corresponding to the AP2-µ2 adaptin-binding motif in the GABAA 
receptor β3 subunit binds to this complex with relatively high affinity in its 
nonphosphorylated state, but not when chemically phosphorylated at S408 and 
S409. The nonphosphorylated version of the peptide alone enhances miniature 
IPSC  (mIPSC) amplitudes and whole-cell GABAA  receptor currents in a 
manner that is occluded by inhibitors of dynamin (Kittler et al., 2005). More 
recently, a tyrosine based AP2-µ2 adaptin-binding motif in the GABAA receptor 
γ2 subunit (Y
365GY
367ECL)  has been identified (Kittler et al., 2008). These 
tyrosine residues are principal sites for phosphorylation by Src kinase (Brandon 
et al., 2001; Moss et al., 1995).  Utilizing nonphosphorylated and 
phosphorylated peptides corresponding to Y365 and Y367, the authors show 
that this high affinity interaction is phospho-dependent (Kittler et al., 2008). 
Introduction of the nonphosphorylated γ2 peptide into neurons induced a large   55 
increase in the mIPSC amplitude that was accompanied by an increase in the 
number of receptors on the cell surface (Kittler et al., 2008). Interestingly, 
codialysis of neurons with both the nonphosphorylated β3 and γ2 subunit 
peptides produced an additive effect on mIPSC amplitudes (Kittler et al., 2008). 
 
Post-endocytic GABAA receptor sorting 
 
The fate of internalized receptors is also another determinant of surface receptor 
levels. Following internalization, GABAA receptors are either rapidly recycled 
back to the neuronal plasma membrane or, over longer time frames, are targeted 
for lysozomal degradation, an endocytic sorting decision that is regulated by the 
Huntingtin-associated protein (HAP)-1. Yeast two-hybrid screens revealed that 
HAP1 interacts with the GABAA receptor β1 subunit but not the α1, γ2, or δ 
subunits (Kittler et al., 2004). Overexpression of HAP1 in cultured neurons has 
been shown to increase the number of receptors on the cell surface at steady-
state that correlates with a dramatic increase in the mean amplitude of mIPSCs 
without affecting the frequency or kinetics of these events (Kittler et al., 2004). 
However, whether HAP1 promotes GABAA receptor recycling or prevents their 
lysozomal degradation is an unresolved issue. Nevertheless, the importance of 
HAP1-dependent regulation of GABAA receptor trafficking is evident in a study 
in which selective suppression of hypothalamic HAP1 by siRNA induced a 
decrease in feeding behavior in mice that was attributed to reduced surface 
expression and activity of GABAA receptors (Sheng et al., 2006). 
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Postsynaptic targeting and clustering of GABAA receptors 
 
The highly selective subcellular localization of GABAA  receptor subtypes 
implies that subunit composition plays a major role in the postsynaptic targeting 
and clustering of these receptors. While the exact molecular mechanisms that 
govern the accumulation of GABAA receptors at inhibitory synapses are not yet 
fully understood, it involves a number of receptor associated proteins and 
cytoskeletal elements that are concentrated at postsynaptic densities (PSDs). 
 
The inhibitory synaptic marker gephyrin is a 93 kDa subsynaptic scaffolding 
protein that was originally implicated in regulating the postsynaptic clustering 
of glycine receptors in the spinal cord by directly binding to the receptor
 β 
subunit  (Meyer et al., 1995).  More recently, data derived from gephyrin 
knockout mice and knockdown experiments
 using antisense oligonucleotides or 
shRNAi have revealed
  that reducing gephyrin expression also leads to an 
extensive loss in the punctate staining of GABAA receptors incorporating a γ2 
subunit together with α2 (but not α1) subunits (Essrich et al., 1998; Jacob
 et al., 
2005; Kneussel et al., 1999; Levi et al., 2004). This suggests the existence of 
both gephyrin-dependent and independent  GABAA  receptor clustering 
mechanisms. As discussed earlier, gephyrin clusters are absent in γ2 subunit 
knockout mice, and the remaining α and β subunit-containing receptors show 
diffuse staining (Essrich et al., 1998). Furthermore, transfection of γ2 subunit-
deficient neurons with chimeric α2/γ2 constructs revealed that the TM4 of the 
γ2 subunit is sufficient for targeting these receptors to postsynaptic sites, but   57 
that both the TM4 and ICD of the γ2 subunit were necessary for recruiting 
gephyrin to the synapse and rescuing GABAergic inhibitory synaptic function 
(Alldred et al., 2005). A role for this receptor associated protein in stabilizing 
previously clustered GABAA  receptors  at the cell surface, rather than their 
specialization at inhibitory synapses, has thus been proposed. Concurrent with 
this, postsynaptic GABAA receptors have been shown to be three times more 
mobile in cells where gephyrin expression has been impaired (Jacob et al., 
2005). Gephyrin is believed to anchor postsynaptic GABAA receptors to the 
plasma membrane by cross-linking the receptor molecule to the tubulin and 
actin cytoskeleton. Gephyrin binds with high affinity to tubulin and as such is 
viewed as a bona fide MAP (Ramming et al., 2000). Gephyrin also mediates an 
indirect interaction with the cytoskeleton by binding to LC1 and LC2 of the 
dynein motor proteins and the microfilament associated proteins belonging to 
the Mena/VASP  family  (Fuhrmann et al., 2002). The membrane-associated 
protein collybistin II is a guanine-nucleotide exchange factor (GEF) that binds 
to and so permits the subsynaptic localization of the otherwise intracellular 
gephyrin, where it directly interacts with and immobilizes specific GABAA 
receptor subtypes  (Harvey et al., 2004; Kins et al., 2000). In addition, the 
dystrophin  glycoprotein complex (DGC) and neuroligin  (NL)-2 bridge the 
synaptic cleft by interacting with presynaptic β-neurexin, promoting 
GABAergic synaptogenesis (reviewed in Tretter and Moss, 2008). 
 
Although gephyrin is found to be concentrated at GABAergic synapses in both 
hippocampal and cortical neurons (where glycine receptor expression is   58 
relatively low), in initial studies using standard biochemical methods it failed to 
copurify with any of the GABAA  receptor subunits. Hence an  intermediate 
linker protein was postulated, the prime candidate being GABARAP - given its 
ability to directly bind the γ2 subunit ICD and gephyrin. However, subsequent 
analysis revealed that GABARAP is not clustered at gephyrin-rich PSDs but 
instead is mainly localized in intracellular compartments including the ER, 
Golgi apparatus and, to some extent, in subsynaptic secretory vesicles (Kittler et 
al., 2001; Wang et al., 1999). This is consistent with a role for this protein in 
intracellular trafficking rather than postsynaptic clustering. In a recent study 
Tretter and colleagues (2008) for the first time provided evidence that gephyrin 
directly binds to the α2 subunit ICD in vitro. This interaction was blocked by 
low concentrations of detergent, providing a possible explanation as to why 
previous attempts to identify a direct association between gephyrin and GABAA 
receptors were unsuccessful. However, under the same conditions only very 
weak binding to α1, β3 and γ2 subunits was observed (Tretter et al., 2008), 
suggesting that the role of these subunits in the postsynaptic accumulation of 
GABAA receptors may be independent of
 the ability of these proteins to directly 
bind gephyrin. The 81 kDa actin-binding protein radixin, a member of the 
ezrin/radixin/moesin (ERM) protein family, has recently been shown to directly 
link the α5 subunit to the cytoskeleton via a radixin-binding motif conserved 
within the ICD of α1-3 and α5 subunits, differing only by two amino acids in 
the α2 subunit (Loebrich et al., 2006). In neurons, both depletion of radixin and 
replacement of the radixin actin-binding motif dramatically decreased α5 
subunit-containing GABAA  receptor clusters without altering total surface   59 
expression levels. Radixin also showed limited colocalization with postsynaptic 
gephyrin, consistent with previous reports that GABAA receptor α5 subunits 
localize mainly at extrasynaptic sites (Brunig et al., 2002; Loebrich et al., 2006). 
However, the mechanisms responsible for the formation of radixin-dependent 
extrasynaptic GABAA receptor clusters remain to be elucidated. 
 
Modulation of GABAA receptor function by post-translational 
modifications 
 
The cell surface stability of GABAA  receptors is  further  regulated by post-
translational modifications such as palmitoylation, ubiquitination and 
phosphorylation.  In addition, these modifications have been implicated in 
altering the biophysical and pharmacological properties of these ligand-gated 
ion channels (reviewed in Arancibia-Carcamo and Moss, 2009). 
 
Palmitoylation 
 
Palmitoylation is the covalent attachment of the saturated fatty acid palmitate to 
cysteine residues of a given protein by the palmitoyl transferase Golgi-specific 
DHHC zinc finger domain protein  (GODZ). Palmitoylation enhances the 
hydrophobicity of proteins and contributes to their membrane association. As 
such it has been shown to be involved in the postsynaptic clustering and 
subcellular trafficking of a number of proteins, including AMPA receptors 
(Hayashi et al., 2005) and the neuronal scaffold proteins PSD-95 and glutamate   60 
receptor-interacting protein  (GRIP)-1  (DeSouza et al., 2002; Smotrys and 
Linder, 2004). It is unique in that it is the only reversible lipid modification and 
thus allows the cell to dynamically regulate the location of specific proteins. In 
a yeast two-hybrid screen, the 34 kDa protein GODZ was identified as a 
GABAA receptor γ2 subunit interacting protein that recognizes a 14 amino acid 
cysteine-rich domain conserved in the ICD of all γ1-3 subunits, N-terminal to 
the GABARAP binding site (Rathenberg et al., 2004). Analysis  of  Cys-Ala 
mutant γ2 constructs in transfected African green monkey kidney (COS-7) cells 
revealed that the γ2 subunit is palmitoylated at all four cysteines within the 
GODZ binding domain (Rathenberg et al., 2004). Mutation of these cysteine 
residues resulted in a loss of GABAA receptor clusters at the cell surface, as did 
drug-induced global inhibition of palmitoylation by Br-palmitate (Rathenberg et 
al., 2004). Likewise, disrupting GODZ function or expression levels using 
dominant negative or RNAi approaches results in a significant reduction in the 
amplitude of mIPSCs attributed to a decrease in postsynaptic GABAA receptor 
number (Fang et al., 2006). From these studies it is evident that palmitoylation 
can dynamically regulate the efficacy of neuronal inhibition by controlling the 
accumulation of GABAA receptors at the postsynaptic membrane, although the 
exact mechanism by which this is achieved is unknown. 
 
Ubiquitination 
 
The regulation of GABAA receptor trafficking by the ubiquitin-related protein 
Plic1 suggests that GABAA  receptors may also be a direct target for 
modification by the polypeptide ubiquitin. The covalent attachment of one or   61 
more copies of the 76-amino acid ubiquitin monomer to lysine residues of target 
proteins is referred to as ubiquitination. Monoubiquitination is reversible and 
serves as an active signal in diverse intracellular trafficking pathways, including 
as a trigger for endocytosis. In contrast, polyubiquitination is required for the 
translocation of proteins from the ER back into the cytosol, where they are 
degraded by the proteasome. Recently, activity-dependent polyubiquitination of 
GABAA receptor β3 subunits has been shown to reduce the stability of newly 
translated and assembled receptors in the ER via a mechanism dependent on the 
activity of the proteasome (Saliba et al., 2007). Coincident with a loss of cell 
surface
 expression levels, chronic blockade of neuronal activity by tetrodotoxin 
(TTX) treatment reduced both the amplitude
 and frequency of mIPSCs (Saliba 
et al., 2007). TTX had no effect on the enhanced functional expression of 
GABAA receptors incorporating β3 subunits in which all twelve lysine residues 
within the ICD of this subunit had been mutated to arginines (β3
K12R). These
 
mutations did not alter GABAA receptor cell surface
 half-life or internalization 
rates, but significantly enhanced receptor insertion into
 the plasma membrane 
(Saliba et al., 2007). 
 
Phosphorylation 
 
Protein phosphorylation is fundamental to the activity of cellular signaling 
networks. It is achieved through protein kinase catalyzed transfer of a phosphate 
group to serine, threonine and/or tyrosine residues of a given protein substrate 
that can be reversed in a dephosphorylation reaction catalyzed by protein 
phosphatases. GABAA receptors are well-established phosphoproteins. Diverse   62 
studies on GABAA receptor phosphorylation have implicated this process in 
altering channel gating, conductance and/or kinetics, sensitivity of the receptors 
to pharmacological agents, protein-protein interactions and membrane 
trafficking (reviewed in Kittler and Moss, 2003). Hence the coordinated activity 
of kinases and phosphatases plays a pivotal role in controlling neuronal 
excitability.  
 
Studies in heterologous expression systems have demonstrated that GABAA 
receptor function, depending on the subtype analyzed, can be differentially 
modulated by phosphorylation of key residues within the ICDs of receptor β1-3 
and γ2 subunits by a number of kinases, including cAMP-dependent protein 
kinase (PKA), calcium/phospholipid-dependent protein kinase (PKC), calcium/ 
calmodulin-dependent kinase II (CaMKII), protein kinase B (PKB - also known 
as Akt), cGMP-dependent protein kinase (PKG) and tyrosine kinases of the Src 
family (summarized in Table 1.2). This is best illustrated by the differential 
modulation of GABAA receptor subtypes by PKA, dependent upon the identity 
of the β subunit. In vitro studies using purified bacterially expressed GST fusion 
proteins combined with site directed mutagenesis revealed that the consensus 
motif for PKA-induced phosphorylation conserved within the ICDs of GABAA 
receptor β1-3 subunits is RRRXSQLK, where S is serine at position 409 in β1 
and β3 subunits (McDonald and Moss, 1997; Moss et al., 1992a) and serine at 
position 410 in the β2 subunit (McDonald and Moss, 1997) and X represents 
either an alanine residue in β1 and β2 subunits or a serine residue at position 
408 in the β3 subunit. However, in contrast to in vitro findings, analysis of  63 
Table 1.2:  GABAA receptor phosphorylation sites 
 
Subunit  Phosphorylation 
site 
Protein kinase 
    In vitro  Heterologous 
cell lines 
Primary 
neurons 
β1  S384 
S409 
 
CaMKII 
PKA, PKC, 
CaMKII, 
PKG 
 
PKA, PKC 
 
β2  S410  PKA, PKC, 
Akt, CaMKII, 
PKG 
PKC, Akt  Akt 
β3  S383 
S408 
S409 
 
CaMKII 
PKC 
PKA, PKC, 
CaMKII, 
PKG 
 
PKA, PKC 
PKA, PKC 
 
 
PKA, PKC 
PKA, PKC 
γ2  S327 
S343 
PKC 
PKC, CaMKII 
   
  S348 
T350 
Y365 
Y367 
CaMKII 
CaMKII 
Src 
Src 
 
 
Src 
Src 
 
Adapted from Brandon et al., 2002   64 
recombinant GABAA receptors in HEK-293 cells have demonstrated that PKA-
induced phosphorylation of the β3 subunit occurs at both S408 and S409 (rather 
than at S409 alone); whereas the β2 subunit is not a substrate for this kinase in 
heterologous expression systems (McDonald et al., 1998). Interestingly, PKA 
was shown to depress GABA-activated currents in HEK-293 cells expressing 
β1 subunit-containing GABAA receptors, whereas in β3 subunit-expressing cells 
a potentiation was observed (McDonald et al., 1998). The latter was attributed 
to the presence of two juxtaposed serine residues (S408 and S409) in β3, as 
selective mutation of S408 to alanine (to structurally resemble the GABAA 
receptor  β1  subunit  at  this  site)  converted  this  potentiation  to  a depression 
(McDonald et al., 1998). On the other hand, PKA had no effect on β2 subunit-
expressing  cells  (McDonald et al., 1998),  which  can  be  accounted  for by the 
selective recruitment of PKA to GABAA  receptor  β1  and  β3,  but  not  β2, 
subunits via the A-kinase anchoring protein (AKAP) of 79 (rat)/150 (human) 
kDa (Brandon et al., 2003).  
 
AKAPs  have also been shown to directly interact with PP2B  and PKC in 
addition to PKA (Klauck et al., 1996; Colledge and Scott, 1999). However, the 
targeting of PP2B and PKC to GABAA  receptors by AKAP remains to be 
investigated. Interestingly, PP2B has been shown to directly bind to the ICD of 
the γ2 subunit, thereby dephosphorylating the receptor and inducing long-term 
depression (LTD) of synaptic inhibition in the CA1 region of the hippocampus, 
a mechanism that is believed to contribute to learning and memory (Wang et al., 
2003).  PKC is recruited to the GABAA  receptor via the anchoring protein   65 
receptor for activated C kinase (RACK)-1 and, like PKA, has different effects 
on receptor function depending on subunit composition. In agreement with the 
findings in vitro all of the β subunit isoforms were found to be a substrate for 
this kinase in HEK-293 cells (Krishek et al., 1994; McDonald et al., 1998; 
Brandon et al., 2000). Functional studies employing site-directed mutagenesis 
have demonstrated a downregulation of receptor activity in response to phorbol 
esters mediated by PKC-induced phosphorylation of β1 S409, β2 S410, γ2S 
S327 and γ2L S327/343. However, the use of a constitutively active catalytic 
domain of PKC  (PKM), produced results contradicting those obtained with 
phorbol esters. In transfected mouse fibroblasts PKM enhanced the response to 
GABA in a manner that was dependent on the phosphorylation of the β1 subunit 
at S409 and the γ2L subunit at S327 and S343 (Lin et al., 1996). The reason for 
this discrepancy  remains unresolved although it has been speculated that 
different PKC isoforms may produce different responses (Song and Messing, 
2005). In contrast, brain-derived neurotrophic factor (BDNF)-induced PKC-
mediated  phosphorylation  of  the  β3  subunit has been shown to transiently 
increase  the amplitude of mIPSCs in cultured neurons, an effect that was 
paralleled by an increase in GABAA receptor cell surface stability (Jovanovic et 
al., 2004). Furthermore, the initial enhancement observed in receptor activity 
was followed by a prolonged depression that was attributed to PP2A-mediated 
dephosphorylation of the β3 subunit (Jovanovic et al., 2004). 
 
No adaptor protein is known for CaMKII, although the kinase is capable of 
coimmunoprecipitating with GABAA receptors from detergent-soluble mouse   66 
brain extracts (Mcainish et al., unpublished data). In vitro studies have revealed 
that the serine/threonine kinase CaMKII directly phosphorylates specific 
residues within the ICDs of GABAA receptor β and γ2 subunits. These include 
S384/409 in β1, S410 in β2 and S383/409 in β3, as well as the γ2 subunit at 
S343 (γ2L only), S348 and T350. Interestingly, the intracellular application of 
purified, active CaMKII failed to modulate the function of GABAA receptors 
heterologously expressed in HEK-293 cells but significantly potentiated the 
amplitudes of whole-cell GABA-activated currents recorded from rat cultured 
cerebellar granule neurons and from recombinant GABAA receptors expressed 
in neuroblastoma-glioma hybrid (NG108-15) cells, implying the contribution of 
some essential neuronal factor (Houston and Smart, 2006).  
 
In addition to binding PKC and the GABAA receptor β subunits, RACK1 also 
binds the tyrosine kinase Src to facilitate the phosphorylation of the γ2 subunit 
on Y365 and Y367 (Brandon et al., 2001; Kittler and Moss, 2003; Moss et al., 
1995). Coexpression of Src with recombinant α1β1γ2 subunit-containing 
GABAA  receptors has been shown to increase whole-cell GABA-activated 
currents in human embryonic kidney (A293) cells, an effect that was abolished 
by site-specific mutagenesis of both of these tyrosine residues to phenylalanines 
(Moss et al., 1995). Interestingly, mutation of these sites led to increased 
phosphorylation of the β1 subunit at Y384 and Y386, which exhibits relatively 
low stoichiometry of phosphorylation in response to Src compared to wild-type 
control (Moss et al., 1995). In primary neuronal cultures, intracellular 
application of sodium vanadate, a potent tyrosine phosphatase inhibitor,   67 
enhanced benzodiazepine-sensitive GABAA receptor function, suggesting high 
endogenous tyrosine kinase and phosphatase activity under basal conditions 
(Moss et al., 1995). 
 
Phosphorylation-dependent GABAA receptor cross-talk 
 
Kinases not only modulate channel function by phosphorylating the receptor 
directly  but also mediate the effect of extracellular stimuli such as  growth 
factors or ‘cross talk’ with other neurotransmitter systems via G protein-coupled 
receptor activation of signal transduction systems. For example, several lines of 
evidence suggest that PKA is involved in the modulation of GABAA receptor 
function by dopamine. The activation of dopamine type-1 (D1) receptors has 
been shown to enhance GABAA  receptor activity via PKA-mediated 
phosphorylation of the  β3  subunit at S408 and S409 in hippocampal slices. 
Interestingly, this phospho-dependent modulation was diminished in PRIP1 
knockout mice that exhibited enhanced protein PP1α activity compared to wild-
type controls (Terunuma et al., 2004). Conversely, inhibition of PKA activity 
via D3 receptor activation causes a reduction in mIPSC amplitude in the nucleus 
accumbens that is attributed to an increase in the phospho-dependent 
endocytosis of GABAA receptor β3 subunits (Chen et al., 2006). Similarly, D4 
receptor agonists have been shown to decrease mIPSCs in globus pallidus 
neurons via inhibition of PKA activity (Shin et al., 2003). In addition to PKA, 
dopamine-mediated modulation of GABAA receptor function has been shown to 
involve PKC via the activation of D2  receptors (Brandon et al., 2002).   68 
Interestingly, D5 receptors have been shown to bind GABAA receptors directly 
and modify their function independently of PKA activity (Liu et al., 2000). 
PKA and PKC  are also involved in mediating the effects of serotonin on 
GABAA receptor function via G protein-coupled 5-HT receptors. Activation of 
postsynaptic  5-HT2  receptors  in  PFC  pyramidal neurons has been shown to 
inhibit GABAA receptor currents via a PKC-mediated pathway (Feng et al., 
2001). In contrast,  5-HT4  receptor activation modulates GABAA  receptor 
currents bi-directionally depending on the basal PKA activation levels; elevated 
levels of PKA activation due to increased neuronal activity have been shown to 
reverse the enhancing effect of 5-HT4 receptor activation to a depression (Cai et 
al., 2002).  
 
Many drugs used to treat psychiatric disease, including antipsychotics and 
antidepressants, act to modulate dopaminergic and serotonergic signaling. 
However, their mechanism of action remains unknown. Given that the 
modulation of dopamine and serotonin receptor function has a common output - 
the modulation of GABAA receptor activity - further exploring the functional 
link between GABAA  receptor phosphorylation and these G protein-coupled 
receptors may enhance our understanding of schizophrenia and depression and 
help to identify novel therapeutic targets with which to control these devastating 
conditions. The work presented in this thesis aims to describe the molecular 
mechanisms that may be involved in the phosphorylation-dependent functional 
expression of GABAA  receptors  and also suggest a role for serotonergic 
signaling in modulating GABAA receptor phosphorylation.   69 
 
 
 
 
 
 
 
 
Methods & Materials   70 
General materials 
 
Chemicals and reagents 
 
All chemicals, unless otherwise specified, were purchased from Sigma-Aldrich. 
Aqueous buffers and solutions were prepared in deioinized water (dH2O). 1mM 
ATP (Promega, Cat# E6011) stock was prepared in dH2O, aliquoted and stored 
at -20°C. [γ-
32P]-ATP (10mCi/ml) and EasyTag™ EXPRESS [
35S]-methionine 
protein labeling mix (11mCi/ml) were purchased from PerkinElmer (Cat# 
NEG002A and NEG772, respectively). 
 
Drugs 
 
1mM okadaic acid (Calbiochem, Cat#  459620), 0.5mM phorbol 12,13-
dibutyrate (PDBu) (Calbiochem,  Cat#  524390), 2.5mM calphostin C 
(Calbiochem,  Cat#  208725)  and 10mM GF-109203X (GFX) (Tocris, Cat# 
0741) stocks were prepared in DMSO. 100mM serotonin-HCl (Sigma-Aldrich, 
Cat#  H9523) and 100mM  R(-)-dimethoxy-4-iodoamphetamine-HCl (DOI) 
(Sigma-Aldrich,  Cat#  D153)  stocks were prepared in dH2O.  Fluoxetine-HCl 
was a generous gift from Wyeth Research (Princeton, NJ)  and  a  2mg/ml 
solution in dH2O was prepared fresh on the day. 
 
Equipment 
 
All centrifugations were carried out in an Eppendorf model 5415R bench-top 
microcentrifuge, Beckman Avanti™ J-20 XP high-performance centrifuge or a   71 
Beckman Optima™  TLX ultracentrifuge. All absorbance readings were 
measured using a Bio-Rad SmartSpec™ 3000 spectrophotometer and a Bio-Rad 
model 680 microplate reader. 
 
Molecular biology 
 
Constructs 
 
A list of all DNA constructs used in this study is given in Table 2.1. Plasmids 
encoding GABAA receptor β subunit intracellular domains (ICDs) were cloned 
into pGEX-4T3, a GST gene fusion vector containing a tac promoter for 
chemically inducible, high level expression in any E. coli host (Brandon et al., 
1999). Plasmids encoding full-length GABAA receptor α/β subunits and AP2-µ2 
adaptin were cloned into pRK5, a mammalian expression vector containing a 
cytomegalovirus (CMV) promoter designed for high level expression of cloned 
genes (Haucke et al., 2000; McDonald et al., 1998). 
 
Growth media 
 
Growth media was made by dissolving 10g of Luria Bertani (LB) broth (Sigma-
Aldrich, Cat# L3022) in 500ml dH2O and autoclaved for sterilization. After 
allowing the LB medium to cool, ampicillin was added to a final concentration 
of 50µg/ml (LB-ampicillin medium).  
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Table 2.1: DNA constructs used in this study 
 
Construct  Description 
GST-β1  GABAA receptor β1 subunit ICD in pGEX-4T3 
GST-β2  GABAA receptor β2 subunit ICD in pGEX-4T3 
GST-β3  GABAA receptor β3 subunit ICD in pGEX-4T3 
GST-β3
S408/9A  GABAA receptor β3
S408/9A subunit ICD in pGEX-4T3 
GST-β3
S408A  GABAA receptor β3
S408A subunit ICD in pGEX-4T3 
GST-β3
S409A  GABAA receptor β3
S409A subunit ICD cloned in pGEX-4T3 
α1  Full-length GABAA receptor α1 subunit in pRK5 
β3  Full-length GABAA receptor β3 subunit in pRK5 
β3
S408/9A  Full-length GABAA receptor β3
S408/9A subunit in pRK5 
µ2  Full-length AP2-µ2 adaptin in pRK5 
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Agar plates 
 
Agar plates were made by dissolving a packet of EZMix™ LB agar powder 
(Sigma-Aldrich, Cat# L7533) in 500ml dH2O, autoclaved for sterilization and 
equilibrated to 55°C in a water bath. Ampicillin was then added to a final 
concentration of 100µg/ml, mixed well and poured into sterile 100mm Petri 
dishes (20ml/dish). The LB-agar-ampicillin plates were allowed to solidify at 
room temperature and then stored at 4°C. 
 
Bacterial strains 
 
BL21 (DE3) pLysS competent cells, [F
– ompT hsdSB (rB
–, mB
–) dcm gal λ(DE3) 
pLysS Cm
r] (Promega, Cat# L1191), were used in GST fusion protein induction 
and expression. XL1-Blue electrocompetent cells, recA1 endA1 gyrA96 thi-1 
hsdR17  supE44  relA1  lac  [F´  proAB  lacI
qZΔM15  Tn10  (Tet
r)] (Stratagene, 
Cat# 200228), were used in plasmid carriage and propagation. 
 
Transformation of bacteria with plasmid DNA 
 
Heat-shock 
Transformation of BL21 (DE3) pLysS competent cells by heat-shock was 
carried out according to manufacturer’s specifications. Briefly,  100μl  of the 
E.coli cells were thawed on ice and mixed with 10μl of plasmid DNA (0.1-
5ng/μl) in a pre-chilled BD Falcon™ polypropylene culture tube. After 30 min 
incubation on ice, the tube was transferred to a water bath set to 42°C for 45 s 
and then immediately returned on ice for 2 min. The cells were then flushed   74 
with 900µl of pre-warmed LB medium and allowed to recover for 1 h at 37°C. 
Transformed cells were selected by plating on LB-agar-ampicillin plates and 
incubating at 37°C for 16 h or until bacterial colonies emerged. 
 
Electroporation 
Plasmid DNA was introduced into XL1-Blue  electrocompetent  cells  by 
electroporation according to manufacturer’s specifications. Briefly, 50μl of the 
E.coli  cells  were thawed on ice and mixed with 1μl  of  plasmid DNA (1-
50ng/μl). This mix was pipetted into a pre-chilled  Bio-Rad Gene Pulser® 
electroporation cuvette (0.1cm gap) and pulsed at 1,700V, 200Ω resistance and 
25µF capacitance using the Bio-Rad Gene Pulser XCell™ electroporator. The 
cells were then flushed with 1ml of pre-warmed LB medium and allowed to 
recover at 37°C for 30 min. Transformed cells were selected by plating on LB-
agar-ampicillin plates and incubating at 37°C for 16 h or until bacterial colonies 
emerged. 
 
Maxi preparation of plasmid DNA 
 
Maxi preparation of plasmid DNA was carried out according to Molecular 
Cloning III - Sambrook and Russell, 2001. A single bacterial colony (grown on 
an LB-ampicillin plate) was picked up using a pipette tip, transferred to a 15ml 
BD Falcon™ tube containing 3ml LB-ampicillin medium and grown for 16 h at 
37°C with vigorous shaking. The bacterial culture was used to inoculate 250ml 
of LB-ampicillin medium and grown for a further 16 h in a 1L conical glass 
flask. Bacterial cells were centrifuged at 5,000 rpm for 15 min at 4°C and the   75 
resultant pellet was resuspended in 5ml Alkaline Solution I (50mM D-glucose, 
25mM Tris-Cl pH 8.0, 10mM EDTA pH 8.0). 10ml Alkaline Solution II (1% 
SDS, 0.2N NaOH) was then added to the solution, mixed gently and allowed to 
stand for 5 min. To this, 7.5ml of ice-cold Alkaline Solution III (60ml 5M K-
acetate, 11.5ml glacial acetic acid, 28.5ml dH2O) was also added, mixed gently 
and allowed to stand for a further 10 min on ice. The mixture was then 
centrifuged at 10,000rpm for 30 min at 4°C. The supernatant was removed and 
added to an equal volume of phenol:chloroform (1:1), mixed well and allowed 
to stand until separation of the two phases had occurred. The upper phase was 
subsequently removed and added to an equal volume of isopropanol, mixed well 
and allowed to stand for 10 min. The mixture was then centrifuged at 
10,000rpm for 15 min and the resultant pellet was resuspended in 5ml dH2O. 
25ml absolute ethanol was added to this, mixed gently and allowed to stand for 
10  min before centrifuging again. The resultant pellet was rinsed with 70% 
ethanol and allowed to dry. Following this, the pellet was resuspended in 3ml 
TE Buffer (10mM Tris-Cl pH 8.0, 1mM EDTA pH 8.0) and 8g of CsCl and 
100µl 10mg/ml EtBr was added to it. The volume was bought up to 8 ml with 
TE Buffer, mixed well, divided into 2 Beckman Quick-Seal® tubes and then 
centrifuged at 100,000rpm  for 16 h. Centrifugation promotes RNA to be 
pelleted at the bottom and the formation of two DNA bands: the upper band is 
linear bacterial DNA and the lower band is supercoiled plasmid DNA. The 
latter was collected using a 5ml syringe and wide-bore hypodermic needle. EtBr 
was removed from the DNA by butanol extraction:  DNA was washed with 
water-saturated butanol a sufficient number of times to remove all EtBr   76 
coloring. CsCl was removed from the DNA by ethanol precipitation: 4 volumes 
of absolute ethanol was added to the DNA together with 0.1 volumes of 3M Na-
acetate, mixed well and allowed to stand for 30 min. The mixture was then 
centrifuged at 10,000rpm for 15 min and the resultant pellet was rinsed with 
70% ethanol and allowed to dry. The purified DNA pellet was resuspended to 
1mg/ml in TE Buffer and stored at 4°C. The concentration of DNA and the 
amount of RNA contamination in the solution was determined by reading the 
absorbance at 260nm (A260) and 280nm (A280), respectively.  
 
The concentration of DNA was calculated using the formula (where f is the 
dilution factor): 
[DNA] (µg/ml) = 50(A260)f 
 
The purity of the DNA solution was calculated using the ratio:  
A260/A280 
 
Agarose gel electrophoresis 
 
6X DNA Loading Dye Buffer (30% glycerol, 0.25% xylene cyanol, 0.25% 
bromophenol blue) was added to 10ng of DNA to a final concentration of 1X 
DNA Loading Dye Buffer. DNA samples and a 1-kb plus DNA ladder (Life 
Technologies, Cat# 10787018) were then resolved by electrophoresis on a 0.9% 
UltraPure™ agarose gel (Invitrogen, Cat# 15510027) prepared in TAE Buffer 
(40mM Tris-acetate, 1mM EDTA pH 8.0) containing 2.5µl 10mg/ml EtBr/50ml 
of gel. Electrophoresis was carried out at 100V in TAE buffer using the Bio-  77 
Rad  Mini-Sub  Cell®  GT  agarose gel electrophoresis system, according to 
manufacturer’s guidelines. DNA bands were visualized using a Bio-Rad Gel 
Doc™ EQ UV transilluminator and Quantity-One™ analysis software.  
 
Cell Biology 
 
Cell line culture 
 
Propagation 
Cells derived from the African green monkey (Cercopithecus aethiops) kidney 
(COS-7) cell line (ATCC,  Cat#  CRL1651) were transferred to  10ml of 
Dulbecco’s Modified Eagle Medium with F12 supplement (DMEM/F12, 1:1) 
(Invitrogen, Cat# 11330032), 10% heat inactivated fetal bovine serum (FBS) 
(Invitrogen, Cat# 26140079) and 1% penicillin/streptomycin (Invitrogen, Cat# 
15140122) then grown in a 100mm culture dish at 37°C in a humidified 5% 
CO2 incubator. Cells were passaged (or subcultured) 1:5 at 70-80% confluence, 
which was carried out by first removing the media by aspiration and washing 
the cells in phosphate-buffered saline (PBS). 1ml of 0.05% trypsin/0.02% 
EDTA (Invitrogen, Cat# 15400054) in PBS was then added to the culture dish 
for 1-2 min at 37°C to detach the cells. Trypsinization was blocked by 
resuspending the cells in 10ml culture medium, which was pipetted up and 
down at least 20 times to ensure efficient dissociation of the cells. 2ml of the 
cell suspension was then transferred to a new culture dish with 8ml of fresh 
culture medium.   78 
Transfection 
COS-7 cells were transiently transfected by electroporation according to 
Molecular Cloning III - Sambrook and Russell, 2001. Briefly, cells passaged 24 
h prior to transfection were trypsinized as described above and then spun down 
by centrifugation at 1000rpm for 5 min. The media was removed by aspiration 
and the cells washed in 10ml Opti-MEM™ reduced-serum medium (Invitrogen, 
Cat# 11058021) and then resuspended in 200µl of Opti-MEM™. To 100µl of 
the cell suspension, 3µg of plasmid DNA was added and transferred to a Bio-
Rad Gene Pulser® electroporation cuvette (0.2cm gap). The cells were pulsed at 
110V  for 20 ms  using the Bio-Rad Gene Pulser XCell™  electroporator. 
Transfected cells were transferred to a 60mm culture dish with 4ml of culture 
medium maintained at 37°C in a humidified 5% CO2 incubator for 48 h (to 
allow translation) prior to experimentation. 
 
Primary neuronal culture 
 
Rat cortical neurons were isolated  as described previously in Banker and 
Goslin, 1988. Briefly, cortices were dissociated from embryonic day 18 (E18) 
Sprague-Dawley rats in 10ml of 0.25% trypsin (Invitrogen, Cat# 25090028) in 
HEPES buffered Hank’s Balanced Salt Solution (HBSS; Invitrogen, Cat# 
14065056) for 15 min at 37°C and subsequently washed 3 times in HBSS to 
clear cells of any further trypsin enzymatic activity. Cells were gently titurated 
using a fire glass polished glass Pasteur pipette and counted using a Neubeauer 
haemocytometer. Dissociated rat cortical neurons were seeded onto 10µg/ml 
poly-L-lysine (PLL) (Sigma, Cat#  P1274)-coated 60mm culture dishes at a   79 
density of 25,000 cells/mm
2 in 4ml Neurobasal™ medium (Invitrogen, Cat# 
21103049) supplemented with 2% B-27 (Invitrogen, Cat# 17504044), 1% L-
glutamine (Invitrogen, Cat# 25030081) and 0.6% D-(+)-glucose solution 
(Sigma-Aldrich, Cat# G8769). Cultured neurons were maintained at 37°C in a 
humidified 5% CO2 incubator (with regular feeding) for 8-10 DIV prior to drug 
treatment. Following treatment, cells were washed 3 times with ice-cold PBS 
prior to further experimentation. 
 
Histology 
 
Animals 
 
2-4 month old C57BL/6 male mice obtained from Jackson Laboratories (Bar 
Harbor, ME) were housed in a temperature-controlled facility with a 12 h light-
dark cycle and fed standard rodent chow and water ad libitum. Animals were 
allowed to acclimatize to these local housing conditions for at least 2 weeks 
prior to experimentation. All procedures were carried out in strict accordance 
with the
 National Institutes of Health Guide for the Care and Use of
 Laboratory 
Animals and were approved by the University of Pennsylvania
  Institutional 
Animal Care and Use Committee. 
 
Acute PFC slice preparation 
 
Preparation of acute PFC  slices was carried out as described previously in 
(Svenningsson et al., 2002). Briefly, C57BL/6 mice (2-4 months old) were   80 
deeply anesthetized with isoflurane and then decapitated at the second cervical 
vertebrae. Brains were carefully removed from the skull and rinsed in ice-cold 
artificial CSF (ACSF; 124mM NaCl, 3mM KCl, 25mM NaHCO3, 2mM CaCl2, 
1mM NaH2PO4, 2mM MgSO4, 10mM D-glucose) equilibrated with 95% O2 and 
5% CO2 to yield a pH of 7.4. The PFC was then cut into 350µm slices using a 
Leica VT1000S vibrating microtome and allowed to recover in ACSF under 
constant oxygenation for 1 h at 32°C prior to drug treatment. Following 
treatment, PFC slices were washed 3 times with ice-cold ACSF and then stored 
at -80°C until assayed. 
 
Focused microwave irradiation of the brain 
 
C57BL/6 mice (2-4 months old) were culled by focused microwave irradiation   
(4.0 kW for 1.2 s) using a Muromachi Kikai small animal microwave according 
to manufacturer’s guidelines. Brains were rapidly removed from the skull and 
either the PFC dissected out and stored at -80°C until assayed, or the whole-
brain kept intact for immunohistochemical analysis (described below). 
 
Biochemistry 
 
GST fusion protein purification 
 
Purification of GST fusion proteins was carried out as described previously in 
Moss et al., 1992. A single bacterial colony (grown on an LB-ampicillin plate) 
was picked up  using a pipette tip, transferred to a 50ml BD Falcon™  tube   81 
containing 15ml LB-ampicillin  medium and grown for 16 h at 37°C  with 
vigorous shaking. A 15ml bacterial culture was used to inoculate 1L of LB-
ampicillin and grown for a further 2-3 h or until the absorbance at 600nm (A600) 
reached 0.4-0.5. Protein expression was then induced by adding isopropylthio-
β-D-galactoside (IPTG) to a final concentration of 0.2mM and by  shaking 
vigorously for 3 h at room temperature. Bacterial protein was centrifuged at 
4,200rpm for 20 min at 4°C and the resultant pellet was resuspended in 10ml 
Buffer A (50mM Tris-Cl  pH 8.0, 10mM EDTA pH 8.0, 25% sucrose), 
centrifuged again and snap-frozen. The bacterial pellet was then thawed on ice 
and resuspended in Buffer B (10mM Tris-Cl pH.7.4, 1mM EDTA pH 8.0) with 
protease inhibitors (PI; 250μg/ml AEBSF, 10µg/ml antipain, 10µg/ml leupeptin 
and 1µg/ml pepstatin). Triton X-100 was added to a final concentration of 1% 
and the mixture was sonicated at full power, 5 times for 30 s each. Following 
sonication, 25ml of Buffer C (20mM HEPES pH 7.6,  100mM KCl, 0.2mM 
EDTA pH 8.0, 20% glycerol)/PI and 400µl aprotinin was added to the cell 
lysate and centrifuged at 35,000rpm for 30 min at 4°C. The supernatant was 
added to 80mg of glutathione agarose beads (pre-swollen in Buffer C/PI) and 
incubated for 2 h on a rotating wheel at 4°C. The beads were washed 5 times for 
10 min each in Buffer C prior to elution, which was carried out once with 1ml 
Elution Buffer (70mM glutathione in Buffer C, pH 7.5)/PI, then twice with 
0.5ml Elution Buffer/PI. Each time the beads were suspended gently in Elution 
Buffer for 15 min and then centrifuged at 3,000rpm for 1 min at 4°C. The 
collected eluant was then pooled and dialysed against 2L of Coupling Buffer 
(0.1M NaHCO3, 0.5M NaCl, pH 8.3) for 16 h at 4°C.   82 
Purified GST fusion protein concentrations were determined using the Bradford 
protein assay reagent (Bio-Rad, Cat# 5000006), according to manufacturer’s 
specifications at A595, and then made up to 1mg/ml, aliquoted and stored at -
80°C.  
 
In vitro kinase assay 
 
In vitro kinase assays were performed essentially as described previously in 
Moss et al., 1992.  
 
Phosphorylation by PKA 
10µl of GST fusion proteins (1µg/µl) was combined with 4µl of 5X PKA Buffer 
(200mM HEPES pH7.5, 100mM MgCl2) and 2µl of 1:10 diluted PKA (2,500 
units) (Promega, Cat# V516A) on ice. For mock reactions, dH2O was 
substituted for PKA. Reaction mixtures were pre-warmed for 1 min at 30°C 
prior to the addition of 4µl of 1mM ATP (to give a final concentration of 
0.2mM ATP) to initiate the reaction. Reactions were incubated for a further 30 
min and then terminated by the addition of an equal volume of 2X SDS Loading 
Dye Buffer. In addition, a parallel assay utilizing [γ-
32P]-ATP:ATP mix (1:9) 
was carried out to allow measurement of the stoichiometry of phosphorylation. 
 
Phosphorylation by PKC 
10µl of GST fusion proteins (1µg/µl) was combined with 2µl of 10X PKC 
Buffer (200mM HEPES pH 7.5, 100mM MgCl2, 5mM CaCl2, 500nM PDBu) 
and 4µl of PKC (10ng/µl) (Millipore, Cat# 14115) on ice. For mock reactions,   83 
dH2O was substituted for PKC. Reaction mixtures were pre-warmed for 1 min 
at 30°C prior to the addition of 4µl of 1mM ATP (to give a final concentration 
of 0.2mM ATP) to initiate the reaction. Reactions were incubated for a further 
30 min and then terminated by the addition of an equal volume of 2X SDS 
Loading Dye Buffer. In addition, a parallel assay utilizing [γ-
32P]-ATP:ATP 
mix (1:9) was carried out to allow measurement of the stoichiometry of 
phosphorylation.  
 
Measurement of the stoichiometry of phosphorylation 
GST fusion proteins that had been subjected to an in vitro kinase assay in the 
presence of [γ-
32P]-ATP  were spotted onto Whatman filter paper and then 
washed 3 times 10 min each with 12.5% TCA to remove any free [γ-
32P]-ATP. 
These were then rinsed in absolute ethanol, allowed to dry and the amount of 
32P incorporated into the samples measured using a liquid scintillation counter. 
In addition, 1% of the [γ-
32P]-ATP:ATP mix was also counted for 
32P to enable 
the  stoichiometry of phosphorylation (mol of 
32P/mol  of protein)  to be 
calculated. 
 
Antibodies 
 
A list of all antibodies used in this study is given in Table 2.2. Total GABAA 
receptor β3 subunit rabbit IgG (anti-total-β3) was raised against GST-β3 (345-
408) and phosphorylation sites S408- and S409-specific GABAA receptor β3 
subunit rabbit IgG  (anti-pS408/9-β3)  against  a  peptide  corresponding  to 
residues 401-412 of the rat β3 subunit chemically phosphorylated at these serine   84 
Table 2.2:  Antibodies used in this study 
 
Primary antibody (IgG)  Source  Dilution 
Polyclonal rabbit anti-total-β3  Cocalico Biologicals 
Antisera# UCL99 
1:2,000 
Polyclonal rabbit anti-pS408/9-β3  Cocalico Biologicals 
Antisera# UP2030 
1:5,000 
Monoclonal mouse anti-AP2-µ2  BD Transduction Labs 
Cat# 611350 
1:2,500 
Monoclonal mouse anti-β-actin  Sigma-Aldrich 
Cat# A3853 
1:25,000 
 
Secondary antibody (IgG)  Source  Dilution 
Polyclonal donkey HRP-anti-rabbit  Amersham  
Cat# NA934V 
1:5,000 
Polyclonal goat HRP-anti-mouse  Pierce  
Cat# 1858413 
1:25,000 
ExactaCruz™ HRP-anti-rabbit  Santa Cruz Biotechnology 
Cat# sc-45043 
1:2,500 
ExactaCruz™ HRP-anti-mouse  Santa Cruz Biotechnology 
Cat# sc-45039 
1:2,500 
Polyclonal goat biotin-anti-rabbit   Vector Laboratories  
Cat# BA1000 
1:500 
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residues (pβ3-pep). The peptide (synthesized at Rockefeller University,  NY, 
USA), was made fully immunogenic by conjugating it to Imject® Maleimide-
Activated mcKLH (Pierce,  Cat#  77605)  according to manufacturer’s 
specifications. Production of antisera against both antigens was carried out at 
Cocalico Biologicals (PA, USA) using the standard company protocol. In brief, 
the procedure consisted of an initial inoculation with 250µg of antigen mixed 
with complete Freund’s adjuvant on day 0. This was followed by a booster 
injection with 100µg of antigen mixed with incomplete Freund’s adjuvant on 
day 14, and two additional boosts with 50µg antigen on days 21 and 49. Two 
weeks after the final boost rabbits were exsanguinated and the antisera were 
purified using affinity columns as described below. 
 
Antibody purification - affinity column assay 
 
Anti-total-β3 and anti-pS408/9-β3 antibodies were purified on GST-β3 fusion 
protein  and  pβ3-pep  coupled to CNBr-activated  Sepharose™  4B  (GE 
Healthcare, Cat# 17043001) gel columns, respectively. 
 
Preparation of affinity columns 
Affinity columns were prepared according to manufacturer’s guidelines. 
Briefly, for each column, 1g of CNBr-activated Sepharose™ 4B freeze-dried 
powder (~3.5ml gel volume) was swollen for 15 min in 200ml 1mM HCl added 
in several aliquots and then washed with 5-gel volumes of Coupling Buffer. 
Antigen coupling to the gel (2mg antigen/column) was carried out overnight on 
a rotating wheel at 4°C. Excess antigen was washed away with 5-gel volumes of   86 
Coupling Buffer and any remaining active groups were blocked with 5-gel 
volumes of 100mM Tris-Cl (pH 8.0) for 2 h on a rotating wheel at 4°C. The gel 
was then packed into a 10ml glass column and uncoupled antigen was washed 
away with 3 cycles of alternating pH. Each cycle consisted of a wash with 5-gel 
volumes of 100mM acetate (pH 4.0) containing  0.5M  NaCl followed by 
100mM Tris-Cl (pH 8.0) containing 0.5M NaCl. Prior to carrying out affinity 
purification of antisera, the column was equilibrated to pH 7.5 by washing with 
10-gel volumes of 10mM Tris-Cl (pH 7.5).  
 
Affinity purification of antisera 
Affinity purification of antisera was carried out according to Harlow and Lane, 
1988. Briefly, antiserum was diluted 1:5 in 10mM Tris-Cl (pH 7.5)/PI  and 
passed through the column 3 times. Non-specific binding was removed by 
washing the column with at least 20-gel volumes of 10mM Tris-Cl (pH 7.5) 
followed by 10mM Tris-Cl (pH 7.5) containing 0.5M NaCl and then again with 
10mM Tris-Cl  (pH 7.5)  alone. Bound antibody was then eluted with 5-gel 
volumes of 100mM glycine (pH 2.5). Eluant was collected in 900µl fractions in 
microfuge tubes containing 100µl 1M Tris-Cl (pH 8.0) to neutralize the IgG 
solution immediately. The IgG solution was then pooled, concentrated and 
exchanged to PBS using a Centricon® Plus-20 centrifugal ultrafiltration device 
(Millipore, Cat# UFC2LTK08).  
 
Purified antibody concentrations were determined by reading the absorbance at 
280nm (A280) and using the extinction coefficient:    87 
A280 1.0 = 0.8mg/ml IgG 
 
Antibodies were made up to 1mg/ml, NaN3 added to a final concentration of 
0.02%, aliquoted and stored at -80°C. 
 
Preparation of cell and tissue extracts 
 
Unless otherwise stated, COS-7 cells and/or rat cortical neurons were lysed in 
30µl of SDS Buffer (1% SDS, 1mM EDTA, 50mM NaF), collected using a cell 
scraper, transferred to a microfuge tube and, following a 1:10 dilution in Triton 
Buffer (1% Triton X-100, 20mM Tris-Cl pH 8.0, 150mM NaCl, 10mM NaF, 
2mM Na3VO4, 10mM Na4P2O7, 5mM EDTA pH 8.0)/PI, briefly sonicated. 
Mouse PFC slices and/or tissue was briefly sonicated in 100µl of SDS Buffer 
and then 1:5 diluted in Triton Buffer/PI. Following lysis, all samples were 
centrifuged at 13,200 rpm for 15 min at 4°C and supernatants or extracts 
collected. Protein concentrations were determined using the Micro-BCA™ 
protein assay kit (Pierce, Cat#  23235), according to manufacturer’s 
specifications at A570, and the volumes adjusted with lysis buffer. 
 
SDS-PAGE 
 
2X or 5X SDS-polyacrylamide gel electrophoresis (PAGE) Loading Dye Buffer 
was added to all protein samples to a final concentration of 1X SDS-PAGE 
Loading Dye Buffer (50mM Tris-Cl pH 8.0/2% SDS/10% glycerol/0.1M DTT/ 
0.1% bromophenol blue) and boiled for 5 min at 100°C. Protein samples with   88 
the appropriate low-range (Bio-Rad, Cat# 1610304) or high-range (Bio-Rad, 
Cat#  1610303) protein molecular weight marker were then resolved by 
electrophoresis on either an 8% (for cell and tissue extracts) or 10% (for GST 
fusion proteins) SDS-PAGE gel (for preparation of SDS-PAGE gels see Table 
2.3). Electrophoresis was carried out at 100V in SDS Running Buffer (25mM 
Tris-base, 250mM glycine, 0.1% SDS) using the Bio-Rad Mini-PROTEAN® 3 
gel electrophoresis system, according to the manufacturer’s guidelines. 
 
Coomassie stain of SDS-PAGE gels 
 
Visualization of proteins resolved by SDS-PAGE was achieved by incubating 
the gel in Coomassie Stain (0.25% brilliant blue R/30% methanol/10% glacial 
acetic acid) for 5 min with agitation. The gel was rinsed with dH2O and 
incubated in Destain (30% methanol/10% glacial acetic acid) for 15 min with 
agitation and then replaced with fresh Destain overnight. The following day the 
gel was incubated in 10% glycerol for 15 min before drying for 1-2 h at 80°C 
on a Bio-Rad model 583 gel dryer, according to the manufacturer’s guidelines. 
 
Electro-transfer of SDS-PAGE gels 
 
After proteins were resolved by SDS-PAGE they were electro-transferred onto 
Hybond™-C Extra nitrocellulose membrane (GE Healthcare, Cat# RPN303E) 
for  16 h  at  30mA in Transfer Buffer (25mM Tris-Cl, 192mM glycine, 0.037% 
SDS and 20% methanol) in a 4°C cold-room using the Bio-Rad Mini Trans-
Blot® electrophoretic transfer system, according to manufacturer’s instructions.   89 
Table 2.3:  Preparation of SDS-PAGE gels 
 
  Resolving gel  Stacking gel 
  8%  10%  5% 
dH2O  4.6  4.0  1.4 
30% acrylamide mix  2.7  3.3    0.33 
1.5M Tris-Cl (pH 8.8)  2.5  2.5  - 
1M Tris-Cl (pH6.8)  -  -    0.25 
10% SDS  0.1  0.1    0.02 
10% APS  0.1  0.1    0.02 
TEMED      0.006      0.004      0.002 
  Volume (ml) 
Adapted from Molecular Cloning III - Sambrook and Russell, 2001   90 
Western blotting 
 
Following electro-transfer of proteins, nitrocellulose membranes were briefly 
immersed in Ponceau Stain (0.1% ponceau S, 5% acetic acid), rinsed with dH2O 
and the positions of the molecular weight marker indicated in pencil. 
Membranes were then blocked with 5% milk in Tris-buffered saline (TBS) 
containing 0.1% Tween®-20 (TBS-T) for 1 h. Next, membranes were incubated 
with primary antibody diluted to its workable concentration in blocking buffer 
for 2 h. Excess antibody was removed by washing membranes 3 times for 5 min 
each wash in TBS-T. The membrane was then incubated with the appropriate 
horseradish peroxidase (HRP)-conjugated secondary antibody diluted to its 
workable concentration in blocking buffer for 1 h. Again, excess antibody was 
removed by washing membranes 3 times for 10 min each wash in TBS-T. It is 
important to note that each of the above incubations and washes were carried 
out with agitation. After discarding the last wash, SuperSignal® West Dura 
Substrate (Pierce, Cat# 34075) was applied to the blots for 5 min to allow 
development of chemiluminscence, and visualized using the Fujifilm LAS-3000 
imaging system and Multi Gauge™ analysis software.  
 
Dot blot assay 
 
1-3µl of pβ3-pep and β3-pep (0.1µg/µl) were  dotted onto nitrocellulose 
membranes that had been pre-soaked in Transfer Buffer and subject to 
immunoblotting with crude antiserum diluted 1:1000, as described below. 
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Overlay assay 
 
GST fusion proteins separated by SDS-PAGE (1µg protein/lane) and electro-
transferred onto nitrocellulose membranes were subsequently blocked with 5% 
BSA in TBS-T for 1 h and then overlaid with 50µl of in vitro translated 
35S-
AP2-μ2  adaptin  reaction mixture (TNT® T7  Quick Coupled 
Transcription/Translation System; Promega, Cat# TM045) in blocking buffer 
for 2 h. Excess radiolabeled protein was removed by washing membranes 3 
times for 10 min each in TBS-T. Bound material was captured by exposing 
membranes to a phosphorimage screen (Bio-Rad, Cat# 1707843) and then 
visualized using the Bio-Rad Molecular Imager™ FX phosphorimager and 
Quantity-One™ analysis software. 
 
Immunoprecipitation assay 
 
Immunoprecipitation assays were carried out using the appropriate 
ExactaCruz™ rabbit (Santa Cruz biotechnology, Cat# sc-45043) and/or mouse 
(Santa Cruz biotechnology, Cat# sc-45039) immunoprecipitation/western 
blotting reagents, according to manufacturer’s guidelines. Briefly, 3µg of anti-
total-β3  antibody was incubated with 40µl of suspended (25% v/v) 
ExactaCruz™ rabbit immunoprecipitation matrix and 500µl of PBS for 1 h on a 
rotating wheel at 4°C. Following this, the anti-total-β3  antibody-
immunoprecipitation matrix complex was pelleted by centrifugation at 
3,000rpm for 1 min at 4°C. The supernatant was then carefully aspirated and 
discarded and the pellet washed 2 times with 500µl of Triton Buffer to remove   92 
excess antibody. After discarding the final wash, detergent-soluble whole-cell 
extracts (prepared from rat cortical neurons, 8-10 DIV, lysed in 300µl of Triton 
Buffer/PI alone) were transferred to the pelleted matrix and incubated for 2 h at 
4°C. Following this, immunoprecipitated material was pelleted by 
centrifugation at 3,000rpm for 1 min at 4°C and the supernatant carefully 
aspirated and discarded. The pellet was then washed 2 times with 500µl of high 
salt (500mM NaCl) Triton Buffer followed by 2 times with Triton Buffer to 
remove nonspecific binding. After discarding the final wash, 40µl of 2X SDS 
Loading Dye Buffer was added to the pelleted matrix and boiled for 5 min at 
100°C. Samples were  then  resolved by SDS-PAGE, electro-transferred onto 
nitrocellulose membrane and subject to western blotting with anti-total-β3, anti-
pS408/9-β3 and anti-AP2-µ2 antibodies and the appropriate HRP-conjugated 
ExactaCruz™ anti-rabbit (Santa Cruz Biotechnology, Cat# sc-45043) and/or 
anti-mouse (Santa Cruz Biotechnology, Cat# sc-45039) secondary antibodies. 
 
Biotinylation cell surface assay 
 
Biotinylation of cell surface proteins was carried out as described in Fairfax et 
al., 2004. Briefly, rat cortical neurons (8-10 DIV) were incubated with 1mg/ml 
EZ-link™ Sulfo-NHS-Biotin (Pierce, Cat# 21217) dissolved in ice-cold PBS 
containing Ca
2+ and Mg
2+ (PBS-CM) (Invitrogen, Cat# 14287072) for 15 min at 
4°C to label surface fractions. Un-reacted biotin was then quenched by washing 
cells twice with Quenching Buffer (50mM glycine, 0.1% BSA in PBS-CM) and 
twice with PBS-CM alone. Cells were then lysed and whole-cell extracts 
incubated with 40µl of suspended (50% v/v) UltraLink® immobilized   93 
NeutrAvidin™ beads (Pierce, Cat# 53150) and 500µl of Triton Buffer/PI for 2 h 
on a rotating wheel at 4°C to pull down biotinylated surface protein fractions. 
Following this, biotinylated material was pelleted by centrifugation at 3,000rpm 
for 1 min at 4°C. The supernatant was then carefully aspirated and discarded 
and the pellet washed 2 times with 500µl of high salt (500mM NaCl) Triton 
Buffer followed by 2 times with Triton Buffer to remove nonspecific binding. 
After discarding the final wash, 20µl of 2X SDS Loading Dye Buffer was added 
to the pelleted matrix and boiled for 5 min at 100°C. Samples were  then 
resolved by SDS-PAGE, electro-transferred onto nitrocellulose membrane and 
subject to western blotting as described above. 
 
Immunohistochemistry 
 
HRP staining of paraffin-embedded brain sections 
 
Preparation and HRP staining of paraffin-embedded brain sections was carried 
out essentially as described previously in (Chi and Chandy, 2007). 
 
Preparation of paraffin-embedded brain sections 
Brains from mice culled by microwave irradiation were fixed in 10% formalin 
for 16 h, washed in dH2O for 30 min and then dehydrated in increasing alcohol 
grade washes: 70% ethanol (x1), 95% ethanol (x1) and absolute ethanol (x3) for 
1 h each. Brains were then cleared with 3 washes in xylene for 1 h each and 
immersed in 3 changes of melted paraffin for 1 h each in a 60°C oven to allow   94 
paraffin to penetrate deep into the cellular structure of the tissue. Paraffin-
embedded brains were allowed to rapidly cool to form paraffin wax blocks and 
the PFC serially sectioned at a thickness of 6µm using a Leica SM2000R 
vibrating microtome. Sections were briefly immersed in a water bath set to 
50°C and then mounted onto positively charged Superfrost® Plus microscope 
slides (Thermo scientific, Cat# 4951+). 
 
Antigen retrieval 
In order to improve the sensitivity and specificity of the immunohistochemical 
analysis, antigen retrieval was performed. Paraffin-embedded  brain  sections 
were first deparaffinized in a 50°C slide warmer for 10 min followed by 2 
washes in xylene for 2 min each. Next, sections were rehydrated in decreasing 
alcohol grade washes: absolute ethanol (x2), 95% ethanol (x2) and 70% ethanol 
(x2) for 2 min each followed by 2 washes in dH2O for 2 min each. Finally, 
antigen retrieval was performed by placing slides in a Coplin jar containing 
100mmM Na-citrate (pH 8.5) and microwaving at maximum power for 
approximately 2 min or until buffer came to a boil. Slides were left in the 
boiling buffer for a further 30 min and then rinsed 2 times with dH2O followed 
by 2 times with PBS. 
 
HRP staining 
In order to minimize volume of antibody required for labeling a liquid-repellent 
slide marker pen was first used to mark around the brain  sections. After 
allowing the liquid-repellent to dry for a few seconds, sections were blocked in   95 
10% goat serum (Vector Laboratories, Cat# S-1000)/1% BSA (Vector 
Laboratories, Cat# SP5050) diluted in PBS containing 0.3% Tween®-20 (PBS-
T). The sections were then incubated with either anti-pS408/9-β3 or anti-total-
β3 antibodies (1:50 diluted in blocking buffer) for 1 h. In addition, a no-primary 
antibody control was included for each experiment. All of the sections were 
then washed 5 times in PBS-T and then incubated with biotin-conjugated anti-
rabbit secondary (1:500 diluted in blocking buffer) for 1 h. Sections were 
washed 3 times with PBS-T followed by 2 times with PBS alone and then 
developed utilizing  HRP-conjugated avidin (Vectastain® ABC kit; Vector 
Labs,  Cat#  PK6100)  with diaminiobenzidine (DAB) (Vector Labs, Ca# 
SK41000) as substrate, according to manufacturer’s specifications. The reaction 
was stopped by washing the sections  5 times  with ice-cold tap water. For 
control experiments sections were also counterstained with 10% cresyl violet, a 
basic synthetic dye that binds acidic components such as RNA-rich ribosomes, 
nuclei, and nucleoli, for 1 min and then washed with tap water until the water 
was clear. After allowing the sections to dry overnight, they were dehydrated in 
increasing alcohol grade washes: 70% ethanol (x2), 95% ethanol (x2) and 
absolute ethanol (x2) for 2 min each. Sections were then cleared with 2 washes 
in xylene for 2 min each and mounted under coverslips with permount (Fisher, 
Cat# SP15100).  
 
Light microscopy 
 
Images of HRP-stained  brain  sections were taken using an Olympus BXJ1 
research microscope (10X objective) equipped with an Olympus DP70 digital   96 
camera. Images were captures as .tif files and edited using Corel Photo-Paint® 
X3 software to enable background subtraction, contrast/brightness adjustments 
and cropping. 
 
     97 
 
 
 
 
 
 
 
Results I 
 
Development and characterization of phosphorylation sites S408/9-specific 
GABAA receptor β3 subunit antibody 
   98 
Introduction 
 
Protein phosphorylation is one of the most extensively studied and ubiquitous 
mechanisms used by neurons to regulate signaling pathways. It is achieved 
through protein kinase catalyzed transfer of a phosphate group to serine, 
threonine and/or tyrosine residues of a given protein substrate that can be 
reversed in a dephosphorylation reaction catalyzed by protein phosphatases. 
Like other post-translation modifications, phosphorylation can modulate protein 
function by inducing a conformational change that can in turn render the protein 
active or inactive, alter its ability to interact with other proteins, determine its 
subcellular localization, and even target it for degradation. Identification and 
quantification of changes in the phosphorylation state of specific proteins is thus 
crucial in defining the function of a given protein and the consequences of its 
reversible phosphorylation. In many cases, a protein can be phosphorylated on 
multiple sites, which can act independently or synergistically when 
phosphorylated simultaneously. It is therefore important to examine the level of 
phosphorylation for individual sites on a given protein in addition to looking at 
the overall level of phosphorylation.  
 
Until recently, the investigation of protein phosphorylation in intact cells and 
tissue was limited to methods employing pre-incubating cells with radioactive 
phosphate to label intracellular ATP pools that would become incorporated in 
the protein upon phosphorylation. Although this method continues to be very 
valuable, it consists of a number of complex and laborious steps when analyzing   99 
the specific site of protein phosphorylation. It is also difficult to ascertain the 
spatiotemporal distribution of the phosphoprotein, since all subsequent 
biochemical analyses using labeled proteins require the cells to be lysed first. 
The advent of antibodies directed against proteins phosphorylated at a specific 
site has made it possible to study protein phosphorylation in situ, allowing for a 
qualitative as well as quantitative analysis of protein phosphorylation, and 
provides a relatively  simple preparation afforded by immunochemical 
methodology. 
 
GABAA  receptors are well-established phosphoproteins. Emerging evidence 
indicates that the function of GABAA  receptors is subject to dynamic 
modulation by phosphorylation. The β1-3 subunit ICDs are of particular interest 
in this context as they contain conserved serine residues (S409 in β1, S410 in β2 
and S408/9 in β3) that can be differentially phosphorylated by a number or 
kinases in purified and recombinant receptor preparations, including PKA and 
PKC (Brandon et al., 2002; Krishek et al., 1994; McDonald et al., 1998; Moss et 
al., 1992). However, the cell signaling molecules responsible for regulating the 
phosphorylation state of native GABAA receptors remains elusive.  
 
Recent studies using the phosphorylation sites S408- and S409-specific GABAA 
receptor  β3  subunit antibody (anti-pS408/9-β3)  have begun to delineate 
neuronal signaling pathways that modulate fast synaptic inhibition by regulating 
GABAA  receptor  β3  subunit phosphorylation and dephosphorylation. For 
example, the activation of tyrosine receptor kinase (Trk)-B neurotrophin   100 
receptors has been shown to induce PKC-mediated phosphorylation of the β3 
subunit, leading to a transient increase in the amplitude of mIPSCs in both 
cortical and hippocampal neurons, an effect that was paralleled by an increase 
in GABAA receptor cell surface stability (Jovanovic et al., 2004). The initial 
enhancement observed in receptor activity was followed by a prolonged 
depression that was attributed to PP2A-mediated dephosphorylation of the β3 
subunit (Jovanovic et al., 2004). In addition, the activation of D1 receptors has 
been shown to enhance GABAA  receptor activity via PKA-mediated 
phosphorylation  of  the  β3  subunit at S408 and S409 in hippocampal slices 
(Terunuma et al., 2004). Interestingly, this phospho-dependent modulation was 
diminished in PRIP-1  knockout  mice  that  exhibited  enhanced  PP1α  activity 
compared to wild-type controls (Terunuma et al., 2004).  
 
Whilst these studies clearly demonstrate that the anti-pS408/9-β3 antibody is an 
invaluable tool in examining the function of the β3 subunit and the significance 
of its interchangeable state of phosphorylation, they do not address the degree 
of phosphorylation in vivo. This is of critical importance as treating isolated 
neural  cells or tissue with various drugs may not yield the same results as 
dosing animals,  given the complex infrastructure of the brain. However, a 
caveat in measuring the in vivo  phosphorylation state  of a given protein is 
ongoing activity of phosphatases postmortem following classical methods of 
euthanasia such as cervical dislocation, which can potentially mask the effects 
of a drug. Focused microwave irradiation is a relatively new method  of 
sacrificing rodents. This irradiation rapidly heats the brain to >90°C in less than   101 
1 s and thereby immediately destroys all enzyme activity at the time of death, 
preserving  the  in vivo  phosphorylation state  of proteins (O’Callaghan and 
Sriram 2004)  and  levels of various neurotransmitters (Butcher et al., 1976; 
Ishikawa et al., 1982; Katsura et al., 1992) and energy metabolites (Delaney and 
Geiger, 1996; Guattari 1989) that otherwise would fluctuate widely as a result 
of postmortem delay.  
 
In this chapter, I report the development of anti-pS408/9-β3 (newly raised in our 
laboratory) to elucidate the role of serotonergic signaling in GABAA receptor β3 
subunit phosphorylation  and functional expression. After confirming the 
phospho- and site-specificity of this antibody by means of western blotting, I 
evaluate the use of focused microwave irradiation to measure  the  in vivo 
phosphorylation state of the GABAA receptor β3 subunit. I go on to address the 
application of this antibody in immunohistochemistry using paraffin-embedded 
brain sections from animals fixed by focused microwave irradiation.   102 
Results 
 
Design and production of anti-pS408/9-β3 antibody 
 
Rabbit anti-pS408/9-β3  antibody was raised against a chemically 
phosphorylated synthetic peptide corresponding to a short region (12 amino 
acids) of the GABAA receptor β3 subunit phosphorylated at S408 and S409 
(pβ3-pep): 
K - T - H - L - R - R - R - S(PO4) - S(PO4) - Q - L – K 
Small peptides usually elicit only a very poor immune response themselves, and 
therefore a cysteine residue was also introduced at the N-terminus of the peptide 
to enable conjugation to a carrier protein, keyhole limpet haemocyanin (KLH), 
which is inherently antigenic. This cysteine residue also allows the peptide to be 
coupled to an affinity column, which was subsequently used to purify the 
antibody following production. In addition, a nonphosphorylated version of the 
otherwise identical peptide (β3-pep)  was also synthesized to later aid in 
antibody characterization. All peptide synthesis was carried out at the 
Rockefeller University (NY, USA).   
 
The antigenic pβ3-pep was used to immunize 3 rabbits: UP-2028, UP-2029 and 
UP-2030 at Cocalico Biologicals (PA, USA), using the standard company 
protocol. In brief, the procedure consisted of an initial inoculation with 250µg 
of antigen mixed with complete Freund’s adjuvant on day 0. This was followed 
by a booster injection with 100µg of antigen mixed with incomplete Freund’s 
adjuvant on day 14, and two additional boosts with 50µg antigen on days 21 and   103 
49. Two weeks after the final boost rabbits were exsanguinated and the serum 
collected. 
 
Characterization of anti-pS408/9-β3 antibody in western blotting 
 
Exsanguinations collected from animals UP-2028, UP-2029 and UP-2030 were 
screened for antisera by dot blot analysis which,  unlike  traditional  western 
blotting techniques, eliminates the need to run a gel or having to do an electro-
transfer and is therefore relatively quick and easy to perform. Nitrocellulose 
membranes were dotted with increasing concentrations (0.1-0.3µg) of pβ3-pep 
and  β3-pep  and analyzed by immunoblotting. Antisera from all  3 animals 
displayed strong immunoreactivity against the immunizing pβ3-pep, but not the 
otherwise identical nonphosphorylated β3-pep (Fig 3.1). Given that a dot blot 
assay is reliable only for a ‘yes-or-no’ answer, the antisera were subjected to a 
second, more stringent antibody screening. 
 
To further scrutinize if UP-2028, UP2029 and UP-2030 antisera specifically 
recognize  the  β3  subunit in its phosphorylated state,  β3  subunit  ICDs were 
expressed as GST fusion proteins and subject to an in vitro phosphorylation 
assay either in the absence or presence of purified PKC. Mock-phosphorylated 
and phosphorylated proteins were then separated by SDS-PAGE and, following 
electro-transfer  onto nitrocellulose membranes, probed with the antisera. 
Immunoblotting with UP-2028, UP-2039 and UP-2030 resulted in a band at the 
predicted molecular mass of GST-β3 (~46 kDa) when phosphorylated by PKC, 
with    no     detectable     (UP-2029     and    UP-2030)    or    weak    (UP-2028)   104 
 
 
Figure 3.1:  Dot blot assay.  UP-2028, UP-2029 and UP-2038 specifically recognize 
phospho- but not nonphospho-S408/9-β3 peptide. 0.1-0.3µg of immunizing phospho-S408/9-
β3 peptide (pβ3-pep) and, the otherwise identical, nonphospho-S408/9-β3 peptide (β3-pep) was 
dotted onto nitrocellulose membranes and immunoblotted with UP-2028, UP-2029 and UP-
2030 antisera.   105 
immunoreactivity  in  the absence of kinase (Fig 3.2). Given that UP-2030 
demonstrated the greatest selectivity for the phosphorylated state of GST-β3 
compared to the other antisera examined, it was selected for purification by 
affinity column assay. 
 
To verify if the affinity-purified anti-pS408/9-β3 antibody still comprised high 
affinity and phospho-specificity for the target protein, GST-β3 fusion proteins 
were again subject to an in vitro phosphorylation assay by PKC and analyzed by 
western blotting. Anti-pS408/9-β3  displayed  robust  immunoreactivity for 
phosphorylated  but not mock-phosphorylated  proteins. To ensure that this 
discrimination was not due to unequal protein loading membranes were also 
probed with anti-total-β3.  In  addition,  phosphorylation of GST-β3  was 
confirmed  by  performing  a  parallel  kinase  assay  with  [γ-
32P]-ATP. 
Phosphorimage analysis of proteins separated by SDS-PAGE revealed a 
32P-
labeled band corresponding to GST-β3 when this fusion protein was incubated 
in the presence, but not in the absence, of kinase (Fig 3.3). 
 
The  ability  of anti-pS408/9-β3  to recognize  the  full length of the GABAA 
receptor  β3  subunit phosphorylated at S408 and S409 was analyzed next in 
COS-7 cells cotransfected with α1 and either β3 or β3
S408/9A. Cells were treated 
with either vehicle or 1µM PDBu in the presence of 1µM okadaic acid for 30 
min and lysed. Equal amounts of protein extracts were then separated by SDS-
PAGE and subject to western blot analysis. Immunoblotting with anti-pS408/9-
β3   demonstrated   that   basal   phosphorylation   of   α1/β3 subunit-containing   106 
 
 
Figure 3.2:  UP-2028, UP-2029 and UP-2030 antisera specifically recognize GST-β3 
phosphorylated  in vitro  by PKC.  GST-β3  fusion  proteins  were  subjected  to  an  in vitro 
phosphorylation assay either in the absence (-) or presence (+) of purified PKC. Proteins 
(1µg/lane) were resolved by SDS-PAGE then electro-transferred onto nitrocellulose membranes 
and immunoblotted with UP-2028, UP-2029 and UP-2030 antisera.   107 
 
 
Figure 3.3:  Affinity purified anti-pS408/9-β3  antibody  specifically  recognizes  GST-β3 
phosphorylated in vitro by PKC.  GST-β3  fusion  proteins  were  subjected  to  an  in  vitro 
phosphorylation assay either in the absence (-) or presence (+) of purified PKC. Proteins 
(1µg/lane) were resolved by SDS-PAGE then electro-transferred onto nitrocellulose membranes 
and immunoblotted with affinity purified anti-pS408/9-β3  and  anti-total-β3  antibodies.  The 
autoradiograph confirms phosphorylation of GST-β3 in a parallel assay utilizing [γ-
32P]-ATP.   108 
recombinant  receptors is enhanced following activation of PKC and 
simultaneous  inhibition of PP1/PP2A activity  respectively,  whereas this 
immunoreactivity (~53 kDa) was absent from cells cotransfected with β3
S408/9A 
(Fig 3.4) and mock transfected controls (data not shown). To confirm that 
reduced expression of β3
S408/9A was not the basis for this lack of recognition, 
membranes were also probed with anti-total-β3, which revealed no significant 
difference in total expression. 
 
To determine if anti-pS408/9-β3  antibody  could be used to examine 
phosphorylation of native GABAA receptor  β3  subunits,  rat cortical  neurons 
were treated with 1µM okadaic acid for increasing time periods and whole-cell 
extracts analyzed by western blotting. At time 0, immunoblotting with anti-
pS408/9-β3  identified  a  band  at  ~58  kDa  that  was  significantly  enhanced 
following okadaic acid treatment for 10 (195.5 ± 19.0%; p<0.01), 20 (263.0 ± 
24.9%; p<0.001) and 30 (363.3 ± 17.6%; p<0.001) min, and also resulted in the 
emergence of another  possibly hyperphosphorylated band, the migration of 
which was slowed with increasing exposure time (~73 kDa at 30 min). 
Interestingly, immunoblotting with anti-total-β3 also identified a band at ~58 
kDa that was significantly enhanced following okadaic acid treatment for 10 
(176.8 ± 6.7%; p<0.05), 20 (347.2 ± 26.5%; p<0.001) and 30 (573.5% ± 30.5%; 
p<0.001) min, in addition to a band at ~53 kDa which remained unchanged (Fig 
3.5). Given that treatment with 1µM okadaic acid for 30 min resulted in the 
greatest  increase in the basal phosphorylation of the  β3  subunit,  this 
concentration and time point was used in subsequent experiments to further  109 
 
 
Figure 3.4:  Anti-pS408/9-β3 antibody specifically recognizes GABAA receptor β3 subunit 
in its phosphorylated state in COS-7 cells. COS-7 cells coexpressing α1 with either wild-type 
(lanes 1 and 2) or S408/9A mutant (lanes 3 and 4) β3 subunit-containing recombinant GABAA 
receptors were treated with either vehicle (-) or 1µM PDBu (a PKC activator) in the presence of 
1µM okadaic acid (a PP1/PP2A inhibitor) (+) for 30 min and subsequently lysed with detergent. 
Whole-cell extracts (1µg protein/lane) were then subjected to western blotting with anti-
pS408/9-β3 and anti-total-β3 antibodies. 
   110 
 
 
Figure 3.5:  Inhibiting PP1/PP2A activity increases anti-pS408/9-β3 immunoreactivity in 
cultured neurons.  Western blot analysis of detergent-soluble whole-cell extracts (30µg 
protein/lane) prepared from rat cortical neurons treated with the PP1/PP2A inhibitor okadaic 
acid (1µM) for the times indicated using anti-pS408/9-β3 and anti-total-β3 antibodies. 
Histogram shows the proportion of GABAA receptor β3 subunits phosphorylated expressed as a 
percentage of 0 min treatment time (**p<0.01, ***p<0.001; one-way ANOVA followed by 
Newman-Keuls multiple comparison test).   111 
evaluate if these slower migrating bands correspond to phosphorylation of the 
GABAA receptor β3 subunit at S408 and S409. 
 
As before, immunoblotting whole cell extracts prepared from rat cortical 
neurons with anti-pS408/9-β3 identified a band at ~58 kDa that was enhanced 
following okadaic acid treatment and also resulted in the emergence of another 
band at ~73 kDa. This immunodetection was prevented when the primary 
antibody was pre-absorbed with molar excess of pβ3-pep but
 not β3-pep (Fig 
3.6). In addition, anti-pS408/9-β3  immunoreactive bands were absent in 
membranes pre-treated  with  λ-PPa,  an  Mn
2+-dependent protein phosphatase 
with activity towards phosphorylated serine, threonine and tyrosine residues. 
Similarly, immunoreactivity of anti-total-β3  for  the  slow  migrating 
phosphorylated state of β3 (~58 kDa), but not for dephosphorylated β3 (~53 
kDa), was abolished under these treatment conditions. In fact, the anti-total-β3 
antibody signal for dephosphorylated β3 was amplified, probably due to freeing 
of antibody available for binding to this region (Fig 3.7). 
 
Like  the immunoreactivity observed in rat cortical neurons, anti-pS408/9-β3 
signal was amplified following okadaic treatment at both ~58 and ~73 kDa in 
mouse PFC slices. However, by contrast the ~73 kDa band was much more 
prominent than was the barely visible ~58 kDa band, which was absent from 
vehicle-treated controls and not detected by the anti-total-β3  antibody.  This 
immunodetection was again abolished in the presence of pβ3-pep (Fig 3.8) and 
dramatically    reduced    following    dephosphorylation   by    λ-PPa   (Fig 3.9),   112 
 
 
Figure 3.6:  Phospho- but not nonphospho-S408/9-β3 peptide blocks immunodetection of 
phosphorylated GABAA  receptor  β3 subunit by anti-pS408/9-β3 antibody in cultured 
neurons.  Western blot analysis of detergent-soluble whole-cell extracts (30µg protein/lane) 
prepared from rat cortical neurons treated with either vehicle (-) or 1µM okadaic acid (+) for 30 
min using anti-pS408/9-β3 antibody either alone (lanes 1 and 2) or pre-incubated with 500 
molar excess of chemically phosphorylated (pβ3-pep, lanes 3 and 4) and nonphosphorylated 
(β3-pep, lanes 5 and 6) S408/9 β3 synthetic peptides. Lanes 7 and 8 indicate total β3. 
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Figure 3.7:  λ-PPa treatment blocks immunodetection of phosphorylated GABAA receptor 
β3 subunit by anti-pS408/9-β3 and anti-total-β3 antibodies in cultured neurons. Western 
blot analysis of detergent-soluble whole-cell extracts (30µg protein/lane) prepared from rat 
cortical neurons treated with either vehicle (-) or 1µM okadaic acid (+) for 30 min. Membranes 
were incubated either in the absence (lanes 1 and 2) or presence (lanes 3 and 4) of λ-PPa and 
then probed with anti-pS408/9-β3 and anti-total-β3 antibodies. 
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Figure 3.8:  Phospho- but not nonphospho-S408/9-β3 peptide blocks immunodetection of 
phosphorylated GABAA receptor β3 subunit by anti-pS408/9-β3 antibody in brain slices. 
Western blot analysis of detergent-soluble  brain  extracts (30µg  protein/lane) prepared from 
C57BL/6 mouse PFC slices treated with either vehicle (-) or 1µM okadaic acid (+) for 30 min, 
using anti- pS408/9-β3 antibody either alone (lanes 1 and 2) or pre-incubated with 500 molar 
excess of chemically phosphorylated (pβ3-pep, lanes 3 and 4) and nonphosphorylated (β3-pep, 
lanes 5 and 6) S408/9 β3 synthetic peptides. Lanes 7 and 8 indicate total β3.   115 
 
 
Figure 3.9:  λ-PPa treatment blocks immunodetection of phosphorylated GABAA receptor 
β3 subunit by anti-pS408/9-β3 antibody in brain slices. Western blot analysis of detergent 
soluble brain extracts (30µg protein/lane) prepared from C57BL/6 mouse PFC slices treated 
with either vehicle (-) or 1µM okadaic acid (+) for 30 min. Membranes were incubated either in 
the absence (lanes 1 and 2) or presence (lanes 3 and 4) of λ-PPa and then probed with anti-
pS408/9-β3 and anti-total-β3 antibodies.   116 
confirming that these slower migrating bands correspond to the GABAA 
receptor β3 subunit phosphorylated at S408 and S409.  
 
Focused microwave irradiation to measure in vivo  GABAA  receptor  β3 
subunit phosphorylation in the brain 
 
To  assess if rapid heat inactivation of enzymes by focused microwave 
irradiation sacrifice can prevent the loss of in vivo levels of GABAA receptor β3 
subunit phosphorylation due to postmortem delay, brain samples from animals 
sacrificed by either cervical dislocation or focused microwave irradiation were 
analyzed by western blotting. The results show significantly (p<0.001) higher 
(244.2%  ±  7.6%) levels of basal phosphorylation in microwaved samples 
compared to those from animals sacrificed by cervical dislocation, as detected 
by anti-pS408/9-β3,  while immunoblotting with the anti-total-β3  antibody 
revealed that total receptor subunit expression was unaffected by the mode of 
euthanasia  (Fig 3.10). Moreover, instant  fixation by focused microwave 
irradiation reduced animal-animal variability seen with sacrifice by cervical 
dislocation, likely due to small but significant differences in the time interval 
between sacrificing the animal and sonication of brain tissue in denaturing lysis 
buffer (Fig 3.11). 
 
Characterization of anti-pS408/9-β3 antibody in immunohistochemistry 
 
Having established that focused microwave irradiation of the brain delivers the 
highest   and   most   consistent levels of in vivo GABAA receptor β3 subunit  117 
 
 
Figure 3.10: Focused microwave irradiation of the brain preserves in vivo  GABAA 
receptor  β3 subunit phosphorylation.  C57BL/6 mice were culled  either  by  cervical 
dislocation (-) or by focused microwave irradiation (+). Brains were rapidly removed from the 
skull, dissected on ice and immediately frozen in liquid nitrogen prior to lysis. Detergent-
soluble PFC extracts (30µg protein/lane) were then subjected to western blotting with anti-
pS408/9-β3 and anti-total-β3 antibodies. Histogram shows the proportion of GABAA receptor 
β3 subunits phosphorylated expressed as a percentage of non-microwave control (***p<0.001; 
Students t test).   118 
 
 
Figure 3.11: Focused microwave irradiation minimizes in vivo GABAA receptor β3 subunit 
phosphorylation animal-animal variability in the brain. C57BL/6 mice were culled either by 
cervical dislocation (□) or by focused microwave irradiation (■). Brains were rapidly removed 
from the skull, dissected on ice and immediately frozen in liquid nitrogen prior to lysis. 
Detergent-soluble PFC extracts (30µg protein/lane) were then subjected to western blotting with 
anti-pS408/9-β3  and  anti-total-β3  antibodies.  Scatter plot shows the proportion of GABAA 
receptor  β3  subunits  phosphorylated  expressed  as  a  percentage  of  non-microwave and 
microwave mean values (***p<0.001; Students t test).   119 
phosphorylation at S408 and S409, this method of fixation was adopted for 
subsequent immunohistochemical analysis of this phosphoprotein. HRP staining 
of paraffin-embedded brain sections with either anti-pS408/9-β3 or anti-total-β3 
antibodies demonstrated that, in vivo, the GABAA receptor β3 subunit is basally 
phosphorylated at S408 and S409 in the PFC (Fig 3.12). Counterstaining with 
cresyl violet, a basic synthetic dye that binds acidic components such as RNA-
rich ribosomes, nuclei, and nucleoli  demonstrates that the HRP staining 
observed in the presence of these antibodies is neuronal-specific.  No  HRP 
staining was observed in the absence of primary antibody (Fig 3.12), confirming 
the validity of this method for measuring the regional and cellular distribution 
this phosphoprotein.   120 
 
 
Figure 3.12: HRP staining of paraffin-embedded brain sections from mice fixed by focused 
microwave irradiation.  Paraffin-embedded  PFC  sections from C57BL/6 mice culled by 
focused microwave irradiation were stained either in the absence (upper panel) or presence 
(lower panels) of primary antibody (brown), counterstained with cresyl violet (purple) and then 
visualized using HRP-conjugated secondary antibody coupled to light microscopy.  
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Discussion 
 
In this chapter, I report the development  of a polyclonal antibody directed 
against the GABAA receptor β3 subunit phosphorylated at sites S408 and S409, 
anti-pS408/9-β3, and its use in characterizing GABAA receptor phosphorylation 
in the brain. Whilst this antibody has been previously described  in our 
laboratory (Jovanovic et al., 2004), it is imperative to ensure the phospho- and 
site-specificity of every new batch of antibody made. Initial screening identified 
positive antisera from all 3 animals tested. These antisera displayed strong 
affinity and highly selective immunoreactivity for the immunizing pβ3-pep but 
not the otherwise identical  nonphosphorylated β3-pep.  Subsequent screening 
using GST-β3 fusion proteins either mock phosphorylated or phosphorylated in 
vitro by PKC revealed that UP-2030 comprised the highest titer compared to the 
other antisera examined, and was therefore selected for purification and subject 
to further screening.  
 
Affinity purified anti-pS408/9-β3 displayed robust and selective 
immunoreactivity for GST-β3 phosphorylated in vitro by PKC, confirming the 
recovery of high affinity phospho-specific antibody following purification. In 
addition, anti-pS408/9-β3 specifically recognized the phosphorylated state of 
full length wild-type, but not S408/9A mutant, α1/β3 subunit-containing 
GABAA  receptors expressed in COS-7 cells, further demonstrating the site-
specificity of the antibody. Consistent with previous studies, the β3 subunit was 
shown to be basally phosphorylated at S408 and S409 (McDonald et al., 1998)   122 
and was enhanced following activation of PKC in the presence of a PP1/PP2A 
inhibitor.  
 
However, given that it is difficult and often misleading to correlate results 
derived from in vitro assay systems, using purified and recombinant receptors 
along with those from isolated cell and tissue preparations, the ability of anti-
pS408/9-β3 to specifically recognize native GABAA  receptor  β3  subunits 
phosphorylated at S408 and S409 in cultured neurons and brain slices was also 
determined. Inhibiting endogenous PP1/PP2A activity in both rat cortical 
neurons and mouse PFC slices dramatically  enhanced basal  phosphorylation 
levels and also slowed the migration of this receptor subunit on a denaturing 
SDS-PAGE gel, as detected by immunoblotting with anti-pS408/9-β3.  This 
finding was confirmed using a competition assay in which the primary antibody 
was pre-absorbed with molar excess of either pβ3-pep or β3-pep, where the 
latter failed to block this immunodetection. Moreover, pre-treating the blots 
with  λ-PPa, which releases phosphate groups from phosphorylated serine, 
threonine and tyrosine residues, also reduced the signal for the slow migrating 
phosphorylated form of the β3 subunit by both the anti-pS408/9-β3 and anti-
total-β3 antibodies.  
 
Together  these results demonstrate that the anti-pS408/9-β3  antibody 
specifically recognizes the GABAA receptor β3 subunit phosphorylated at S408 
and S409, and that phosphorylation reduces the electrophoretic mobility of this 
protein. The slowed migration of this phospho-protein may be explained by the   123 
presence of SDS-resistant domains which are unfolded as a result of 
phosphorylation. However, further experiments using urea gradient-PAGE to 
monitor the denaturant-induced unfolding of this phosphoprotein is necessary to 
examine this phenomenon.  
 
Having characterized the phospho-  and site-specificity of anti-pS408/9-β3 
antibody, the use of focused microwave irradiation in measuring in vivo 
GABAA receptor β3 subunit phosphorylation in the brain was determined by 
western blotting. Consistent with previous reports, this mode of sacrifice 
delivered the highest and most consistent levels of phosphorylation when 
compared with cervical dislocation (Hebert and O’Callaghan, 2000; Hossain et 
al., 1994; Jope et al., 1991; Mobley and Gonzalez, 1991; O’Callaghan and 
Sriram, 2004; O’Callaghan et al., 1998; Snyder et al., 2000), confirming that 
focused microwave irradiation of the brain preserves in vivo GABAA receptor 
β3 subunit phosphorylation. Conversely, a dramatic loss and variability in the 
phosphorylation state of this receptor subunit was seen following sacrifice by 
cervical dislocation, despite every attempt made to minimize the time-interval 
between sacrificing the animal and sample preparation. These results indicate 
that classical methods of euthanasia will not prove suitable for most in vivo 
phosphoprotein analysis, and that rapid heat inactivation of enzymes by focused 
microwave irradiation of the brain may be required to achieve biologically 
meaningful data. Given the marked regional and cellular distribution of any 
given phosphoprotein, the application of anti-pS408/9-β3  in 
immunohistochemistry was also confirmed in the brains of animals fixed by   124 
focused microwave irradiation. However, it will also be interesting to address 
the practicality of this antibody in immunofluorescence staining, which would 
enable costaining with other proteins and/or markers of interest. 
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Results II 
 
Phospho-dependent modulation of GABAA receptor β3 subunit  
functional expression 
   126 
Introduction 
 
Altering the number of postsynaptic GABAA  receptors accessible to 
neurotransmitter represent one of the most powerful mechanisms used by 
neurons to regulate the efficacy of inhibitory synaptic transmission (Kittler et 
al., 2000; Kittler and Moss, 2003; Nusser et al., 1998a, 1997). Given the critical 
role of these receptors in controlling neuronal excitability and animal behavior, 
it is unsurprising that the molecular mechanisms underlying the expression and 
stability of cell surface GABAA receptor populations have been an active area 
of research for the past decade. 
 
GABAA  receptors have been shown to be localized in clathrin-coated pits 
suggesting that they undergo classical clathrin-mediated endocytosis, a process 
that is further dependent on dynamin for endocytic vesicle formation. AP2 is a 
central component in the formation of these vesicles, forming a link between 
membrane proteins and clathrin which forms the outer layer of the coat. 
Internalized receptors are then either subjected to rapid recycling or are targeted 
for lysozomal degradation, an endocytic sorting decision that is regulated by 
HAP1 (Kittler et al., 2004). Changes in the rates of receptor endocytosis and/or 
endocytic sorting thus play significant roles in the postsynaptic modulation of 
GABAA receptor-mediated synaptic inhibition. 
 
Given the pivotal role of the AP2 complex in clathrin-mediated endocytosis, a 
possible approach  to alter the rate of receptor internalization would be to   127 
modulate the interaction between the AP2 complex and endocytic motifs in cell 
surface receptors that destine the receptor to be internalized. An atypical AP2-
binding motif conserved within the ICD  of all GABAA  receptor  β  subunit 
isoforms has recently been identified (KTHLRRRSSQLK in the β3 subunit) 
(Kittler et al., 2005). This motif, which is enriched in lysine and arginine 
residues, also incorporates the major sites of phosphorylation for PKA and PKC 
within this class of receptor subunits - S409 in β1, S410 in β2 and S408/9 in β3 
(Moss et al., 1992; Krishek et al., 1994; Brandon et al., 2002). In vitro binding 
studies have revealed that the µ2 adaptin of the AP2 complex was able to bind 
the β3 subunit in its dephosphorylated state but not when phosphorylated by 
PKA or PKC. This phospho-dependent interaction was also found to modulate 
mIPSC amplitudes and whole-cell GABAA receptor currents in a manner that 
was occluded by inhibitors of dynamin (Kittler et al., 2005).  
 
Although these findings provide evidence of  an interaction between the µ2 
adaptin of the AP2 complex and the GABAA  receptor  β3  subunit  that  is 
negatively regulated by phosphorylation in vitro, in this chapter the effect of 
GABAA receptor β3 subunit phosphorylation on AP2-µ2 adaptin binding is also 
addressed  in cultured neurons.  Utilizing an overlay assay with radiolabeled 
AP2-µ2 adaptin, I first confirm and extend previous in vitro binding studies to 
show that binding to this complex is dependent on the phosphorylation state of 
GABAA receptor β1, β2 and β3 subunit isoforms and that, in the case of the β3 
subunit, S409, but not S408, is critical for this phospho-dependent interaction. I 
then go on to demonstrate that coimmunoprecipitation of these proteins is   128 
greatly reduced in cultured neurons treated with okadaic acid, a potent inhibitor 
of S408 and S409 dephosphorylation (Jovanovic et al., 2004). Finally, I show 
that this reduction in coimmunoprecipitation is accompanied by a corresponding 
increase in the number of biotin-labeled GABAA receptor β3 subunits on the 
cell surface.   129 
Results 
 
AP2-µ2  adaptin binding to  GABAA  receptor  β  subunits is negatively 
regulated by phosphorylation in vitro 
 
Recent studies have demonstrated that a basic-rich motif localized within the 
ICD of all GABAA receptor β subunit isoforms is capable of directly interacting 
with the µ2 adaptin of the AP2 complex in vitro. Interestingly, this binding 
region overlaps with conserved serine residues that are known substrates for 
several serine/threonine kinases, including PKA and PKC and, in the case of the 
β3 subunit, phosphorylation of S408 and S409 has been shown to block this 
interaction in vitro (Kittler et al., 2005).  
 
To determine if AP2-µ2 adaptin binding to GABAA receptor β1 and β2 subunits 
is also negatively regulated by phosphorylation, GST fusion protein constructs 
encoding ICDs of the β1, β2 and β3 subunits were subjected to an in vitro 
phosphorylation assay by PKA. Mock-phosphorylated and phosphorylated 
proteins (1, 3 and 10µg/lane) were then separated by SDS-PAGE and, following 
electro-transfer onto nitrocellulose membranes, overlayed with [
35S]-
methionine-labeled AP2-μ2 adaptin (
35S-µ2). Bound radiolabeled protein was 
detected by phosphorimaging and normalized to mock-phosphorylated 
coomassie stain. 
35S-µ2 binding was expressed as a percentage of ‘maximal’ 
binding to 10µg mock-phosphorylated controls and the resultant binding curves 
used to derive the apparent dissociation constants (Kd, concentration of fusion 
protein giving rise to half-maximal binding) as a measure of relative binding   130 
affinities for mock-phosphorylated and phosphorylated GST-β1,  β2  and  β3 
fusion proteins in this assay (Fig 4.1).  Given  that  Kd  has molar units, the 
following conversion was used: 
 
 
 
Where: Volume = 10µl; Molecular weight = 43, 42 and 45 kDa for GST-β1, β2 
and β3 fusion proteins, respectively. 
 
It was found that 
35S-µ2 binding affinity of GST-β1 (Kd = 3.1µM) was ~1.6-fold 
lower and that of GST-β2 (Kd = 3.5µM) ~1.7-fold lower when phosphorylated 
in vitro by PKA (Kd = 5.0µM and 6.0µM, respectively). In contrast, a ~5.2-fold 
decrease in binding affinity was observed for phospho-GST-β3 (Kd = 20.2µM) 
compared to mock-phosphorylated control (Kd = 3.9µM). Further analysis of 
35S-µ2 binding within the linear range (i.e. to 1µg of fusion proteins) revealed a 
significant (p<0.001) decrease in binding to the phosphorylated state of GST-β1 
(41.8 ± 6.4%), β2 (37.8 ± 5.2%) and GST-β3 (6.3 ± 1.3%) fusion proteins, 
expressed as a percentage of mock-phosphorylated controls (Fig 4.2). In this 
study, the stoichiometry of phosphorylation achieved was much higher for 
GST-β3 (0.7mol/mol) than for GST-β1 (0.3mol/mol) and β2 (0.4mol/mol), as 
measured in a parallel in vitro kinase assay utilizing [γ-
32P]-ATP (see methods). 
This may in part explain the more dramatic effect seen with the phosphorylated 
state of GST-β3 compared to the other β subunit isoforms. 
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Figure 4.1:   PKA-induced phosphorylation of GST-β1, β2 and β3 fusion proteins shifts 
35S-µ2 binding curves to the right in vitro. GST-β1, β2 and β3 fusion proteins were subjected 
to an in vitro phosphorylation assay either in the absence ( □)  or presence (■) of purified PKA. 
Mock-phosphorylated and phosphorylated proteins (1, 3 or 10µg/lane) were separated by SDS-
PAGE and, following electro-transfer onto nitrocellulose membranes, overlayed with in vitro 
translated 
35S-μ2. Bound material was visualized by phosphorimaging and normalized to mock-
phosphorylated  coomassie  stain.  Binding curves  show 
35S-µ2 binding to fusion proteins 
expressed as a percentage of 10µg mock-phosphorylated controls, set to a value of 100%. 
Micrograms of fusion protein giving rise to half-maximal binding (dashed line) were 
subsequently used to calculate Kd (see text).   132 
 
 
Figure 4.2:  PKA-induced phosphorylation decreases 
35S-µ2 binding to GST-β1, β2 and β3 
fusion proteins in vitro.  GST-β1,  β2  and  β3 fusion proteins were  subjected to in vitro 
phosphorylation either in the absence (-) or presence (+) of purified PKA. Mock-phosphorylated 
and phosphorylated proteins (1µg/lane) were separated by SDS-PAGE then electro-transferred 
onto nitrocellulose membrane and overlayed with in vitro translated 
35S-μ2. Bound material was 
visualized by phosphorimaging (upper panel) and normalized to coomassie stain (middle panel). 
The stoichiometry of phosphorylation was measured in a parallel assay utilizing [γ-
32P]-ATP 
(lower panel). Histogram shows 
35S-μ2 binding to fusion proteins expressed as a percentage of 
mock-phosphorylated controls (***p<0.001; one-way ANOVA followed by a Newman-Keuls 
multiple comparison test).   133 
S409 (but not S408) of the GABAA receptor β3 subunit is critical for AP2-
µ2 adaptin binding in vitro 
 
In the previous study, phosphorylation by PKA was shown to completely 
abolish AP2-µ2 adaptin binding to GST-β3. Given that S409, but not S408, is a 
substrate for this kinase in vitro (McDonald and Moss, 1997), it was speculated 
that this interaction was dependent on the presence of S409 alone. To pinpoint 
the serine residue(s) critical for binding to the µ2 adaptin of the AP2 complex, 
β3 subunit ICDs bearing various serine-to-alanine mutations (S408/9A, S408A 
and S409A) were constructed by site-directed mutagenesis and expressed as 
GST fusion proteins. Again utilizing an overlay assay, GST-β3 wild-type and 
serine-alanine mutants were examined for their ability to bind 
35S-μ2. 
Phosphorimage analysis revealed significantly (p<0.001) decreased 
35S-µ2 
binding in the S408/9A mutant (58.0 ± 5.6% compared to wild-type control). 
Interestingly, mutating only the serine at position 409 to an alanine was 
sufficient to mimic this effect (63.7 ± 2.1% compared to wild-type control). 
Conversely,  the  S408A mutant  exhibited a significant (p<0.001) increase in 
bound 
35S-µ2  (112.5  ±  1.1% compared to wild-type control) (Fig 4.3), 
indicating that not only is the serine at position 408 not required for AP2-µ2 
adaptin binding in vitro, but that this interaction is more pronounced when this 
residue is mutated to an alanine.  
 
I went on to repeat  this experiment using GST-β3  wild-type and serine-to-
alanine mutant fusion proteins that had been subjected to in vitro 
phosphorylation by PKC, a kinase that is known to phosphorylate both S408  134 
   
 
Figure 4.3:  Selective mutation of S409 but not S408 decreases 
35S-µ2 binding to GST-β3 
fusion proteins in vitro.  GST-β3  wild-type, S408/9A, S408A and S409A mutant  fusion 
proteins were separated by SDS-PAGE (1µg protein/lane) and,  following electro-transfer onto 
nitrocellulose membranes,  overlayed with  in vitro  translated 
35S-μ2. Bound material was 
visualized by autoradiography (top panel) and normalized to coomassie stain (bottom panel). 
Histogram shows 
35S-μ2 binding to fusion proteins expressed as a percentage of GST-β3 wild-
type control (*p<0.05, **p<0.01, ***p<0.001; one-way ANOVA followed by a Newman-Keuls 
multiple comparison test).   135 
and S409 (McDonald and Moss, 1997). In agreement with the findings from the 
previous study, 
35S-µ2  binding to wild-type GST-β3  fusion protein was 
significantly (p<0.001) reduced by phosphorylation (64.9 ± 2.8% compared to 
mock-phosphorylated control. The smaller effect observed in this experiment, 
may in part be explained by the lower level of phosphorylation stoichiometry 
observed in this experiment (0.4mol/mol). Phosphorylating only S409 (i.e. in 
the S408A mutant) also significantly (p<0.05) blocked this interaction (65.5 ± 
10.3% compared to mock-phosphorylated control), while subjecting the S409A 
mutant to phosphorylation did not further influence the reduction in binding 
seen as a result of this mutation (94.4 ±  7.5% compared to mock-
phosphorylated control). This difference is not likely due to differences in the 
stoichiometry of phosphorylation as these were relatively similar (0.4 and 
0.3mol/mol, respectively). No difference in binding was observed in the 
S408/9A mutant (99.8 ± 6.3% compared to mock-phosphorylated control) in 
which both sites of serine phosphorylation had  been replaced with  alanine 
residues (Fig 4.4). This is consistent with the background level of 
phosphorylation stoichiometry seen with this mutant (0.07mol/mol). Together 
these findings indicate that it is the serine at position 409 and not that at 408 of 
β3 that is critical for AP2-µ2 adaptin binding in vitro, and that this interaction is 
negatively regulated by phosphorylation.  
 
AP2-µ2 adaptin binding to the GABAA receptor β3 subunit is negatively 
regulated by phosphorylation in cultured neurons 
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Figure 4.4:  Selective PKC-induced phosphorylation of S409 but not S408 decreases 
35S-µ2 
binding to GST-β3 fusion proteins in vitro. GST-β3 wild-type, S408/9A, S408A and S409A 
mutant fusion proteins were subjected to an in vitro phosphorylation assay either in the absence 
(-) or  presence (+) of  purified PKC.  Mock-phosphorylated and phosphorylated proteins 
(1µg/lane) were separated by SDS-PAGE then electro-transferred onto nitrocellulose membrane 
and overlayed with in vitro translated 
35S-μ2. Bound material was visualized by autoradiography 
(upper panel) and normalized to coomassie  stain (middle panel). The stoichiometry of 
phosphorylation was measured in a parallel assay utilizing [γ-
32P]-ATP (lower panel). 
Histogram shows 
35S-μ2 binding to fusion proteins expressed as a percentage of mock- 
phosphorylated controls (***p<0.001; one-way ANOVA followed by a Newman-Keuls 
multiple comparison test).   137 
In order to examine if binding of AP2-µ2 adaptin to the GABAA receptor β3 
subunit is dependent on the phosphorylation state of native receptor protein, rat 
cortical neurons were treated with either vehicle or 1µM okadaic acid for 30 
min and lysed under non-denaturing conditions to preserve protein-protein 
interactions. GABAA receptor β3 subunits were then immunoprecipitated with 
anti-total-β3  antibodies and analyzed by immunoblotting with antibodies 
against AP2-µ2 adaptin. After controlling for recovery of GABAA receptor β3 
subunits, okadaic acid significantly (p<0.001) decreased the level of associated 
AP2-µ2 adaptin (43.0 ± 0.7% of vehicle-treated control) without affecting total 
expression levels. This effect was paralleled by a significant (p<0.01) increase 
in the phosphorylation state  of immunoprecipitated protein, as detected by 
immunoblotting with anti-pS408/9-β3  (215.3  ±  10.3% of vehicle-treated 
control) (Fig 4.5). 
 
Phosphorylation enhances the cell surface stability of GABAA receptor β3 
subunits in cultured neurons 
 
A reduction in the binding of AP2-µ2 adaptin would be predicted to lead to an 
accumulation of GABAA receptor β3 subunits on the cell surface, attributed to a 
decrease in their endocytosis from the plasma membrane. To test this, rat 
cortical neurons treated with either vehicle or okadaic acid were incubated with 
NHS-Biotin to label surface fractions. Following cell lysis, biotinylated proteins 
were purified on avidin and analyzed by western blotting. After normalizing to 
total fractions, okadaic acid significantly increased the proportion of GABAA 
receptor β3 subunits on the cell surface (167 ± 17% of vehicle-treated control;   138 
 
 
Figure 4.5:  Inhibiting  PP1/PP2A activity decreases coimmunoprecipitation of AP2-µ2 
adaptin with GABAA receptor β3 subunits in cultured neurons. Rat cortical neurons were 
treated with either vehicle (-) or 1µM okadaic acid (+) for 30 min and detergent-soluble whole-
cell  extracts immunoprecipitated with either control IgG or anti-total-β3  antibodies. 
Immunoprecipitated (IP) and total (10% input; In) fractions were then analyzed by 
immunoblotting. Histogram shows co-IP of AP2-μ2 adaptin with GABAA receptor β3 subunits 
expressed as a percentage of vehicle-treated control (***p<0.001; Student’s t test).   139 
p<0.001). Under the same conditions, immunoblotting with anti-pS408/9-β3 
revealed a concomitant increase in the phosphorylation state  of cell surface 
protein (229 ± 26% of vehicle-treated control) (Fig 4.6).   140 
 
 
Figure 4.6:  Inhibiting PP1/PP2A activity increases biotin-labeled  GABAA  receptor  β3 
subunits  on the surface in cultured neurons.  Rat cortical neurons treated with either      
vehicle (-) or 1µM okadaic acid (+) for 30 min were labeled with NHS-Biotin and detergent-
soluble whole-cell extracts purified on avidin. Surface and 10% of input (In) fractions were then 
analyzed by immunoblotting. Histograms show the phosphorylated and total GABAA receptor 
β3 subunit levels on the surface normalized to input and expressed as a percentage of vehicle-
treated control (*p<0.001; Student’s t test).   141 
Discussion 
 
Inhibitory synaptic transmission is reliant upon the accumulation of GABAA 
receptors at postsynaptic sites, a process that is regulated by their relative rates 
of exo-  and endocytosis (reviewed in Jacob et al., 2008). At steady-state 
significant rates of GABAA receptor endocytosis is apparent in heterologous 
and neuronal systems and is believed to occur predominantly via a clathrin-
mediated pathway, with approximately 25% of β3 subunit-containing receptors 
being internalized within 30 minutes (Kittler et al., 2004). Recruitment of 
GABAA receptors into endocytic vesicles is facilitated via the interactions of 
receptor β1-3 and γ2 subunit ICDs with the μ2 adaptin of the AP2 complex. In 
the case of the β3 subunit,  in vitro  binding studies have revealed that this 
interaction is negatively regulated by phosphorylation of S408 and S409, which 
lie  within the basic-rich AP2-µ2 adaptin-binding motif (Kittler et al., 2008, 
2005, 2001).  
 
In this chapter, the µ2 adaptin of the AP2 complex was shown to preferentially 
bind to GABAA  receptor  β 1,  β 2  a s  w e l l  a s  β 3   subunit  ICDs in their 
dephosphorylated  state  in vitro  and in cultured neurons.  The reduction in 
binding observed following okadaic acid treatment of cultured neurons was 
accompanied by an increase in the cell surface stability of endogenous GABAA 
receptor β3 subunits. Furthermore, S409, but not S408, of the GABAA receptor 
β3 subunit was shown to be critical for this phospho-dependent interaction. In 
contrast, selectively mutating the S408 to an alanine (to structurally resemble   142 
GABAA  receptor  β1 and β2 subunits at this site)  resulted in an increase in 
affinity of the β3 subunit for the AP2-µ2 adaptin. 
 
To directly visualize the effect of S408/9A mutation on membrane trafficking, 
fluorescent GABAA  receptor  β3 subunits capable of interacting with 
bungaratoxin  were subsequently  employed in confocal imaging studies. 
Importantly these modifications have previously been shown to be functionally 
silent (Bogdanov et al., 2006). In agreement with the in vitro binding data, 
hippocampal neurons expressing pHBBS-β3
S408/9A subunits exhibited reduced 
endocytosis leading to enhanced accumulation at the cell surface at both 
synaptic and extrasynaptic sites  (Jacob et al., 2009).  This finding is not 
unexpected given that GABAA  receptors have recently been reported to be 
inserted into and removed from the plasma membrane exclusively at 
extrasynaptic sites and to diffuse laterally to access postsynaptic sites, where 
they are tethered by interactions with the subsynaptic cytoskeleton (Bogdanov 
et al., 2006).  Despite the dramatic increase in the density of postsynaptic 
GABAA receptors, no significant alterations in the size of the presynapse were 
observed  (Jacob et al., 2009), consistent with prior studies showing little 
evidence of presynaptic compensation with changes in postsynaptic GABAA 
receptor number (Jacob et al., 2005; Kneussel et al., 2001, 1999; Levi et al., 
2004). Intriguingly, while analyzing the cell surface distributions of wild-type 
and S408/9A mutant pHBBS-tagged β3 subunit-containing GABAA receptors, 
an apparent increase in long, filopodia-like spines on neurons expressing the 
latter was noted. This deficit in spine maturity was reversed by pharmacological   143 
blockade of GABAA receptors. Therefore, regulating the efficacy of synaptic 
inhibition by modulating GABAA receptor membrane trafficking may play a 
critical role in regulating spinogenesis and, thus, synaptic plasticity. 
 
Consistent with this, increased postsynaptic accumulation of pHBBS-tagged β3 
subunit-containing GABAA  receptors in response to S408/9A mutation was 
shown to concomitantly enhance both the amplitude and frequency of mIPSCs 
(Jacob et al., 2009). A possible explanation for the observed increase in the 
frequency of events is the recruitment of mIPSCs previously below the 
threshold of detection. A decrease in the rise time of mIPSCs was also observed 
in these cultures, indicating that in addition to altering GABAA  receptor 
endocytosis, mutation (or modification by phosphorylation) of S408/9 may also 
modulate channel kinetics  (Jacob et al,2009).  In a study by McDonald and 
colleagues (1998) phosphorylation of recombinant GABAA receptor β3 subunits 
at S408 and S409 by PKA was shown to enhance GABA-activated currents in 
HEK-293 cells. Interestingly, selectively mutating S408 to alanine switched this 
potentiation into a depression, comparable  to  that  of  β1  subunit-containing 
receptors that are phosphorylated solely on S409 (reviewed in Moss and Smart, 
1996;  Smart,  1997).  In  contrast,  β2  subunit-containing receptors were not 
affected by PKA, in line with the inability of this kinase to phosphorylate full-
length GABAA receptor β2 subunits in vivo. It was further reported that the 
phospho-dependent modulation of β1 and β3 subunit-containing receptors was 
most likely due to altered channel gating and/or conductance as no 
accompanying changes in cell surface number were  observed. Whilst these   144 
findings contradict those from this study, in which phosphorylation of GABAA 
receptor β1 and β3 subunits at S409 would be predicted to increase the efficacy 
of synaptic inhibition by virtue of increased cell surface stability, they support 
the notion that S408 and S409 of the β3 subunit have opposing roles in the 
phospho-dependent modulation of GABAA  receptor function,  offering  a 
molecular mechanism to regulate the efficacy of neuronal inhibition in a 
synapse-specific manner. 
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Results III 
 
Serotonergic modulation of GABAA receptor β3 subunit  
phosphorylation and cell surface stability 
   146 
Introduction 
 
The  serotonergic  system  is involved in the regulation of diverse 
psychophysiological processes including emotion, perception and cognition 
(reviewed in Buhot, 1997; Davidson et al., 2000 and Manji et al., 2001). To 
date, fifteen serotonin receptor subtypes have been identified. These have been 
divided into seven different subclasses on the basis of conserved structures and 
signaling mechanisms (reviewed in Martin et al., 1998): 5-HT1A-F and 5-HT5A-B 
receptor subtypes couple to Gi/o proteins to inhibit adenylate cyclase; 5-HT2A-C 
receptors couple to Gq/11 proteins to stimulate the hydrolysis of phospholipids; 
5-HT4, 5-HT6 and 5-HT7 receptor subtypes couple to Gs proteins to stimulate 
adenylate cyclase,  and 5-HT3  receptors are ligand-gated sodium/calcium 
channels (Martin et al., 1998).  
 
Several lines of electrophysiological evidence indicate that serotonin receptors 
are involved in the complex regulation of GABAergic inhibitory transmission in 
the PFC. Activation of postsynaptic 5-HT2 receptors in cultured PFC pyramidal 
neurons has been shown to inhibit GABAA  receptor currents via a PKC-
mediated pathway (Feng et al., 2001). In contrast, 5-HT4 receptor activation 
modulates GABAA  receptor currents bi-directionally  depending on the basal 
PKA activation levels; elevated levels of PKA activation due to increased 
neuronal activity have been shown to reverse the enhancing effect of 5-HT4 
receptor activation to a depression (Cai et al., 2002). The involvement of these 
kinases in the serotonergic modulation of GABAA receptor function suggests   147 
that phosphorylation of GABAA  receptors  subunits may be the molecular 
mechanism underlying this phenomenon.  As modifications  in serotonergic 
signaling have long been implicated in the etiology of mood disorders and their 
alleviation, such functional cross-talk may play a critical role in controlling the 
efficacy of synaptic inhibition under both normal and pathological conditions. 
Moreover, this potential mechanism may underpin the antidepressant and/or 
anxiolytic effects of selective SSRIs such as fluoxetine (Prozac™). 
 
In this chapter, using anti-pS408/9-β3 antibody I show that serotonin treatment 
of rat cortical neurons significantly increases the phosphorylation state of the 
GABAA receptor β3 subunit in a manner that is dependent upon the activity of 
PKC. The involvement of this kinase suggests that 5-HT2 receptors may be the 
receptor subtype responsible for mediating this effect. Therefore, using 5-HT2 
receptor subtype-specific compounds in acute PFC slices, I further elucidate the 
role that this receptor subtype plays in mediating the serotonergic modulation of 
GABAA receptor β3 subunit phosphorylation. In order to address the role of 
serotonergic signaling in vivo, fluoxetine-treated mice were culled by focused 
microwave irradiation and analyzed by western blotting. To further scrutinize 
the regional and cellular distribution of fluoxetine-induced increase in GABAA 
receptor  β3  subunit  phosphorylation, paraffin-embedded  brain  sections from 
mice culled by focused microwave irradiation were examined by 
immunohistochemistry.   148 
Results 
 
Serotonin enhances GABAA  receptor  β3 subunit phosphorylation  via  a 
PKC-mediated pathway in cultured neurons 
 
To examine the effect of serotonin on GABAA  receptor  β3 subunit 
phosphorylation, rat cortical neurons were treated with 100µM serotonin for 
varying times and detergent-soluble whole-cell extracts analyzed by western 
blotting. At time 0, immunoblotting with anti-pS408/9-β3 identified a band at 
~58 kDa that was significantly enhanced following serotonin treatment for 5 
(151.8 ± 10.2%; p<0.01), 15 (178.1 ± 17.3%; p<0.001) and 30 (145.6 ± 9.3%; 
p<0.01) min. As seen previously (see Fig 3.5), immunoblotting with anti-total-
β3 also identified a likely-phosphorylated band at ~58 kDa. However, unlike 
that seen with okadaic acid, serotonin treatment did not significantly increase 
this immunoreactivity, possibly due to a comparatively lower stoichiometry of 
phosphorylation. Immunodetection at ~53 kDa by anti-total-β3 (the predicted 
molecular mass of the GABAA receptor β3 subunit) remained unchanged at all 
time points tested, indicating no change in total β3 subunit expression under 
these treatment conditions (Fig 5.1).  
 
SSRIs such as fluoxetine increase the availability of serotonin at the synapse by 
blocking reuptake of this neurotransmitter. Whilst there was a trend towards an 
increase (118.2 ± 5.2%) in the proportion of β3 subunits phosphorylated in rat 
cortical neurons treated with 10µM fluoxetine alone for 12 min, this was not  149 
 
 
Figure 5.1:  Serotonin increases GABAA receptor β3 subunit phosphorylation in cultured 
neurons.  Western blot analysis of detergent-soluble whole-cell extracts (30µg protein/lane) 
prepared from rat cortical neurons treated with serotonin (100µM) for the times indicated, using 
anti-pS408/9-β3 and anti-total-β3 antibodies.  Histogram shows the proportion of GABAA 
receptor  β3  subunits  phosphorylated  expressed  as  a  percentage  of  0  min  treatment time 
(**p<0.01, ***p<0.001; one-way ANOVA followed by Newman-Keuls multiple comparison 
test).   150 
found to be significant (p>0.05) (Fig 5.2). However, pre-treating neurons with 
10µM of fluoxetine for 2 min before adding 100µM serotonin in the presence of 
fluoxetine  for a further 10 min resulted in a significant (p<0.001) increase 
(159.3 ± 17.6%) in the proportion of β3 subunits phosphorylated as compared to 
vehicle-treated control and significantly (p<0.05) potentiated the effect of 
serotonin alone (144.8 ± 8.7; p<0.01) (Fig 5.2). 
 
Interestingly,  treatment with 100µM serotonin for 10 min also significantly 
(p<0.001) increased (255.7 ±  11.5%) the phosphorylation state  of PKC 
compared to vehicle-treated control, as detected by immunoblotting with an 
antibody directed against PKC-α phosphorylated at S657 (anti-pPKC) (Fig 5.3). 
Under the same conditions, immunoblotting with anti-PKC revealed no change 
in the total expression of PKC-α, β, γ (Fig 5.3), indicating a selective increase in 
the activation of this kinase. To determine if serotonin-induced increase in 
GABAA  receptor  β3  subunit  phosphorylation  is  PKC-dependent, rat cortical 
neurons were treated with serotonin either in the absence or presence of 
calphostin C, a potent inhibitor of PKC. Treatment with 100µM serotonin alone 
for 10 min resulted in a significant (p<0.001) increase (144.8 ± 8.7%) in the 
proportion  of  β3  subunits  phosphorylated  as  compared to vehicle-treated 
control. This effect was blocked in the presence of and following 20 min pre-
treatment with 2.5µM calphostin C and, similar to treatment with calphostin C 
alone (49.5 ±  0.5%; p<0.01), induced a significant decrease in basal 
phosphorylation levels (56.0 ± 0.0%; p<0.01) (Fig 5.4). 
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Figure 5.2:  Serotonin-induced increase in GABAA receptor β3 subunit phosphorylation is 
potentiated by fluoxetine in cultured neurons.  Western blot analysis of detergent-soluble 
whole-cell extracts (30µg protein/lane) prepared from rat cortical neurons treated with either 
vehicle for 12 min (-/-), 10µM fluoxetine for 12 min (+/-), 100µM serotonin for 10 min (-/+), or 
pre-treated with fluoxetine for 2 min and  then,  in the presence of this SSRI,  treated with 
serotonin for a further 10 min (+/+). Histogram shows the proportion of GABAA receptor β3 
subunits phosphorylated expressed as a percentage of vehicle-treated control (**p<0.01, 
***p<0.001; one-way ANOVA followed by Newman-Keuls multiple comparison test.               
# p<0.05; Student’s t test).   152 
 
 
Figure 5.3:  Serotonin increases PKC phosphorylation in cultured neurons. Western blot 
analysis of detergent-soluble whole-cell extracts (30µg protein/lane) prepared from rat cortical 
neurons treated with either vehicle (-) or 100µM serotonin (+) for 10 min using anti-pPKC and 
anti-total-PKC antibodies. Histogram shows the proportion of PKC phosphorylated expressed as 
a percentage of vehicle control (***p<0.001; Student’s t test).   153 
 
 
Figure 5.4:  Serotonin-induced increase in GABAA receptor β3 subunit phosphorylation is 
blocked by calphostin C in cultured neurons.  Western blot analysis of detergent-soluble 
whole-cell extracts (30µg protein/lane) prepared from rat cortical neurons treated with either 
vehicle for 30 min (-/-), 100µM serotonin for 10 min (-/+), 2.5µM calphostin C for 30 min (+/-), 
or pre-treated with calphostin C for 20 min and then, in the presence of this PKC inhibitor, 
treated with serotonin for a further 10 min (+/+). Histogram shows the proportion of GABAA 
receptor  β3  subunits  phosphorylated  expressed  as  a  percentage  of  vehicle-treated control 
(**p<0.01, ***p<0.001; one-way ANOVA followed by Newman-Keuls multiple comparison 
test).   154 
Serotonin enhances GABAA  receptor  β3  subunit  cell  surface  stability  in 
cultured neurons 
 
To examine if serotonin-induced increase in GABAA  receptor  β3  subunit 
phosphorylation translates to an increase in receptor accumulation on the 
plasma membrane, rat cortical neurons treated with either vehicle or 100µM 
serotonin  for 10 min were subject to a cell surface biotinylation assay and 
detergent-soluble whole-cell extracts  analyzed by western blotting. After 
normalizing to total fractions, serotonin significantly (p<0.05) increased the 
proportion of GABAA receptor β3 subunits on the cell surface (130.3 ± 6.4%) of 
vehicle-treated control (Fig 5.5).  
 
5-HT2 receptors modulate PKC-mediated GABAA receptor β3 subunit in 
brain slices 
 
The involvement of PKC in the serotonergic modulation of GABAA receptor β3 
subunit phosphorylation suggests that 5-HT2  receptors may be the receptor 
subtype responsible for mediating this effect. To test this, acute PFC slices were 
treated with 1, 10 and 100µM of the 5HT2 receptor agonist DOI for varying 
time periods  and  detergent-soluble  extracts  analyzed by western blotting. 
Analysis of the results at the 0 and 15 min time points revealed a significant 
increase in β3 subunit phosphorylation with 1 and 10µM DOI (190.2 ± 16.5%; 
p<0.01  and  182.3  ±  21.9%;  p<0.001, respectively),  whereas a  significant 
(p<0.01) decrease (33.5 ± 9.7%) was observed with 100µM DOI (Fig 5.6). The 
effect of treatment with 10µM DOI for 15 min was blocked in the presence  155 
 
 
Figure 5.5:  Serotonin increases  biotin-labeled  GABAA  receptor  β3  subunits  on the 
surface in cultured neurons. Rat cortical neurons treated with either vehicle (-) or 100µM 
serotonin  (+) for 10  min were labeled with NHS-Biotin and detergent-soluble whole-cell 
extracts purified on avidin. Surface and 10% of input (In) fractions were then analyzed by 
immunoblotting. Histograms show the total GABAA receptor β3 subunit levels on the surface 
normalized to input and expressed as a percentage of vehicle-treated control (*p<0.05; Student’s 
t test).   156 
 
 
Figure 5.6:  DOI increases GABAA receptor β3 subunit phosphorylation in brain slices. 
Western blot analysis of detergent-soluble brain  extracts (30µg protein/lane) prepared from 
C57BL/6 mouse PFC slices treated with 1, 10 or 100µM DOI for the times indicated using anti-
pS408/9-β3 and anti-total-β3 antibodies. Histogram shows the proportion of GABAA receptor 
β3  subunits  phosphorylated  in  response  to  15  min  treatment  with  DOI  (1,  10  and 100µM) 
expressed as a percentage of vehicle-treated (0µM DOI) control (**p<0.01, ***p<0.001; one-
way ANOVA followed by Newman-Keuls multiple comparison test).   157 
of and following 15 min pre-treatment with 10µM GFX (a potent inhibitor of 
PKC) and, similar to GFX alone (36 ± 8.7%; p<0.01), induced a significant 
decrease in basal phosphorylation levels (27.8 ± 7.9%; p<0.05) (Fig 5.7). Taken 
together, these findings suggest that serotonergic modulation of PKC-mediated 
GABAA receptor β3 subunit phosphorylation and cell surface stability is in part 
dependent upon the activation of 5HT2 receptors.  
 
Fluoxetine enhances GABAA  receptor  β3  subunit  phosphorylation  in a 
region-specific manner in vivo 
 
In order to address the role of serotonergic signaling in vivo, mice were injected 
intraperitonealy  (i.p.)  with 20mg/kg fluoxetine and then culled 1 h later by 
focused microwave irradiation. This dose of fluoxetine was chosen on the basis 
that previous behavioral studies have demonstrated a reduction in the time spent 
immobile in the tail-suspension test (Svenningsson et al., 2007), an accepted 
measure of antidepressant efficacy. Western blot analysis of detergent-soluble 
PFC extracts revealed a significant (p<0.001) increase (175.8 ± 11.0%) in the 
proportion of GABAA  receptor  β3  subunits  phosphorylated  compared  to 
vehicle-treated  control  without altering total subunit expression  (Fig 5.8). 
Furthermore, immunohistochemical analysis of paraffin-embedded  PFC 
sections revealed that the GABAA receptor β3 subunit is basally phosphorylated 
in certain limbic regions of the PFC. Phosphorylation of the β3 subunit was 
enhanced following fluoxetine treatment in the anterior cingulate cortex, but not 
the endopiriform cortex, above its already high level of basal phosphorylation, 
whereas total subunit expression remained unchanged (Fig   5.9).  In   addition,      158 
 
 
Figure 5.7:  DOI-induced increase in GABAA  receptor  β3  subunit phosphorylation is 
blocked by GFX  in brain slices.  Western blot analysis of detergent-soluble brain  extracts 
(30µg protein/lane) prepared from C57BL/6 mouse PFC slices treated with either vehicle (-/-), 
10µM DOI for 15 min (-/+), 10µM GFX for 30 min (+/-), or pre-treated with GFX for 15 min 
and then, in the presence of this PKC inhibitor, treated with DOI for a further 15 min (+/+). 
Histogram shows the proportion of GABAA receptor β3 subunits phosphorylated expressed as a 
percentage of vehicle-treated control (**p<0.01, ***p<0.001; one-way ANOVA followed by 
Newman-Keuls multiple comparison test).   159 
 
 
Figure 5.8:  Fluoxetine treatment increases GABAA receptor β3 subunit phosphorylation 
in vivo. C57BL/6 mice were dosed with either vehicle or 20mg/kg fluoxetine i.p. and then 
culled  1 h later by focused microwave irradiation. Detergent-soluble  PFC extracts (30µg 
protein/lane) were then subjected to western blotting with anti-pS408/9-β3  and  anti-total-β3 
antibodies. Histogram shows the proportion of GABAA receptor β3 subunits phosphorylated 
expressed as a percentage of vehicle-treated control (***p<0.001; Students t test).   160 
 
 
Figure 5.9:  Regional and cellular distribution of fluoxetine-induced increase in GABAA 
receptor  β3  subunit  phosphorylation  in  the  PFC.  C57BL/6 mice were dosed with either 
vehicle or 20mg/kg fluoxetine i.p. and then culled 1 h later by focused microwave irradiation. 
Paraffin-embedded PFC sections were  then  stained with anti-pS408/9-β3  and  anti-total-β3 
antibodies  and  visualized using HRP-conjugated secondary antibody coupled to  light 
microscopy.   161 
immunostaining hippocampal sections with anti-pS408/9-β3 demonstrated that 
the GABAA  receptor  β3  subunit  is  basally phosphorylated  mainly  in the 
granular layer of the dentate gyrus and the pyramidal cell layer of CA1-CA3 
subfields  (Fig 5.10). Consistent with  this,  high levels of anti-total-β3 
immunoreactivity was observed in these brain regions (Fig 5.10). Interestingly, 
fluoxetine treatment specifically increased anti-pS408/9-β3  staining in the 
dentate gyrus and CA3, but not CA1,  hippocampal subfields,  whereas no 
change in anti-total-β3  antibody  staining  was  detected  under the same 
conditions (Fig 5.10).    162 
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Figure 5.10: Regional and cellular distribution of fluoxetine-induced increase in GABAA 
receptor β3 subunit phosphorylation in the hippocampal formation. C57BL/6 mice were 
dosed  with either vehicle or 20mg/kg fluoxetine i.p. and then  culled  1 h later by focused 
microwave irradiation. Paraffin-embedded hippocampal sections of were then stained with anti-
pS408/9-β3  and  anti-total-β3  antibodies  and  visualized using HRP-conjugated secondary 
antibody coupled to light microscopy. 
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Discussion 
 
In this chapter serotonin treatment of rat cortical neurons  was  shown  to 
significantly  enhance  the  phosphorylation state  of  the  GABAA  receptor  β3 
subunit at S408/9.  This effect was  significantly  potentiated by the SSRI 
fluoxetine. SSRIs act selectively at the serotonin transporter (SERT) to inhibit 
reuptake and subsequent degradation of serotonin in the presynaptic cleft. 
However, the absence of seronotonergic neurons in these cultures indicates 
fluoxetine action independent of its role in serotonergic signaling. In addition to 
its actions as an SSRI, fluoxetine has been reported to directly interact with the 
GABAA receptor complex (Derry et al., 2007; Goren et al., 2007; Robinson et 
al., 2003; Tunnicliff et al., 1999) that may account for the observed effects of 
fluoxetine on the phosphorylation of the receptor β3 subunit at S408/9.  
 
Interestingly, serotonin treatment concomitantly enhanced the phosphorylation 
of PKC-α, indicating an increase in the activity of this kinase following 5-HT 
receptor activation. In accordance with this, serotonin-induced increase in 
GABAA receptor β3 subunit phosphorylation was blocked in the presence of 
and following pre-treatment with calphostin C, a potent inhibitor of PKC. The 
involvement of PKC in the serotonergic modulation of GABAA  receptor β3 
subunit phosphorylation points towards the 5-HT2  receptor as the receptor 
subtype responsible for mediating this effect. Activation of Gq/11  protein-
coupled 5-HT2 receptors
 stimulates the phospholipase C (PLC)-β isoform and 
the release
  of ionsitol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG) 
through the hydrolysis of phospholipids, which can  in turn activate PKC.   165 
However, serotonin can also activate PKA via Gs protein-coupled 5-HT4, 5-HT6 
and 5-HT7 receptors. Further experiments are thus necessary to elucidate the 
role these signaling pathways play in regulating serotonin-induced  S408/9 
phosphorylation and the stability of GABAA  receptor  β  subunits  on  the  cell 
surface. 
 
The role of serotonergic signaling in GABAA receptor phosphorylation was also 
addressed in vivo in this chapter. Acute systemic administration of fluoxetine 
was shown to significantly enhance the phosphorylation state of the GABAA 
receptor  β3  subunit  at  S408/9  in mice subjected  to focused  microwave 
irradiation of the brain in a region-specific manner. In the PFC, this increase 
was localized to the anterior cingulate cortex, an important neural substrate for 
the integration of emotional, cognitive and physiological information as well as 
the coordination of responses to anticipated stimuli. An increase in receptor 
phosphorylation was also observed in the dentate gyrus and the CA3 subfield of 
the hippocampus, which plays important roles in long-term memory and spatial 
navigation.  Chronic  SSRI treatment has been shown to increase adult 
neurogenesis and synaptic plasticity in the dentate gyrus in a time-course that 
parallels the therapeutic time-lag associated with antidepressant therapy 
(Malberg et al., 2000; Santarelli et al., 2003; Wang et al., 2008); however, the 
effects of SSRIs on cognitive function are complex and contradictory (Li et al., 
2008; Majlessi and Naghdi, 2002; Valluzzi and Chan, 2007). 
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Summary 
 
S408/9 phosphorylation enhances the functional expression of β3 subunit-
containing GABAA receptors  
 
Activity-dependent changes in the number of postsynaptic GABAA receptors 
accessible to neurotransmitter represent  a potent mechanism  underlying the 
functional plasticity of GABAergic synapses (Kittler and Moss, 2003; Kittler et 
al., 2000; Nusser et al., 1998a; 1997). Moreover, changes in the trafficking of 
GABAA receptors to and from postsynaptic membrane sites may contribute to 
the etiology and/or manifestation of a wide  range of neurological and 
psychiatric disorders. The major focus of this thesis was  thus  to detail  the 
cellular and molecular mechanisms that control the expression and stability of 
cell surface GABAA receptor populations at inhibitory synapses.  
 
Recent experimental observations have  suggested  that the trafficking  of 
GABAA receptors is subject to dynamic modulation by phosphorylation and that 
the β subunits play a key role in this phospho-dependent regulation (Kittler et 
al., 2005). In this study, phosphorylation of conserved serine residues (S409 in 
β1, S410 in β2 and S408/9 in β3) by either PKA or PKC was found to reduce 
[
35S]-methionine-labeled  AP2-μ2  adaptin  binding to GST fusion proteins 
encoding the ICDs of GABAA  receptor  β1-3 subunit isoforms in vitro. 
Moreover, mutation of S408/9 to alanines was shown to mimic the effects of 
phosphorylation and decrease binding of the β3 subunit to the µ2 adaptin of the 
AP2 complex. In cultured neurons, okadaic acid (a potent inhibitor of S408/9   168 
dephosphorylation) was shown to dramatically reduce the amount of AP2-µ2 
adaptin coimmunoprecipitated with GABAA  receptor  β3  subunits  and,  in 
parallel,  enhance the stability of biotin-labeled receptors at the cell surface. 
Furthermore, GABAA receptors incorporating pHBBS-β3
S408/9A subunits have 
been shown to exhibit increases in the number and size of inhibitory synapses 
together with enhanced synaptic inhibition, a phenomenon that was found to 
reduce spine maturity  (Jacob et al., 2009).  As  β  subunits  are  essential 
components of all GABAA  receptor subtypes, these results suggest that 
phosphorylation may be a universal mechanism used by all neurons to control 
neuronal excitation, synaptic plasticity and animal behavior. 
 
Modulation of GABAA receptor phosphorylation by serotonergic signaling 
may underlie the therapeutic efficacy of SSRIs 
 
Serotonergic pathways arising from the raphé nuclei in the brainstem innervate 
a wide range of structures thought to be involved in the pathogenesis of mood 
disorders such as depression, including the PFC, hippocampus and amygdala. 
Interestingly, in depressed patients and in animal models reduced GABA levels 
have been reported in the plasma, CSF and various brain regions including the 
PFC  and hippocampus.  Increased benzodiazepine-sensitive GABAA  receptor 
binding sites were also documented in the post-mortem brains of depressed 
suicide victims  (Cheetham et al., 1988; Manchon et a., 1987), which could 
possibly be the result of an adaptive mechanism to overcome the decrease in 
GABA activity. 
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Given that recent studies have implicated PKA and PKC in the mediation of 
serotonergic  modulation of GABAA  receptor  activity  in the PFC,  it was 
speculated that phosphorylation of GABAA receptor β subunits may underlie 
this regulation. To address this, a phospho-specific antibody directed against β3 
at S408/9 was developed. Immunoblotting with anti-pS408/9-β3 demonstrated a 
PKC-dependent increase in the phosphorylation state of GABAA receptor β3 
subunits following enhanced 5-HT2 receptor activation ex vivo.  
 
The role of serotonergic signaling in GABAA  receptor  β3  subunit 
phosphorylation  at S408/9 was examined  in vivo  by utilizing focused 
microwave irradiation, which prevents rapid dephosphorylation of proteins as a 
result of postmortem delay  associated with  classical methods of sacrifice 
(O’Callaghan and Sriram 2004).  Consistent with this,  focused microwave 
irradiation  delivered  the highest and most consistent levels of basal S408/9 
phosphorylation when compared with cervical dislocation  in western blot 
analysis. This was enhanced following acute systemic fluoxetine administration 
at a dose  correlating with antidepressant  efficacy  in accepted behavioral 
paradigms. Given the marked regional and cellular distribution of any given 
phosphoprotein, microwaved brains were also subject to immunohistochemical 
analysis. In the PFC, fluoxetine treatment was shown to increase S408/9 
phosphorylation in the anterior cingulate cortex, but not the endopiriform cortex 
above its already high level of basal phosphorylation.  Results from 
neuroimaging studies have implicated the anterior cingulate cortex in 
depression and anxiety disorders (Mayberg et al., 2000; Brody et al., 2001) and   170 
the perception of pain (Rainville et al., 1997, Ventafridda et al., 2003). Since 
SSRI binding to SERT is particularly high in this brain region, this may explain 
the effectiveness of SSRIs in alleviating mood and pain disorders.  
 
The hippocampal formation is also a known target for antidepressant treatment. 
Acute systemic fluoxetine was shown to specifically enhance  S408/9 
phosphorylation in the granular layer of the dentate gyrus and the pyramidal cell 
layer of the CA3 subfield. Chronic SSRI treatment has been shown to increase 
adult neurogenesis in the dentate gyrus, which is thought to contribute to the 
delayed onset of therapeutic efficacy (Malberg et al., 2000; Santarelli et al., 
2003; Wang et al., 2008).  Both newborn and existing granule cells of the 
dentate gyrus give rise to axons that form the mossy fiber pathway that project 
to CA3 pyramidal cells, a brain region that has been shown to be critically 
involved in the acquisition and memory consolidation of spatial information 
(Stupien et al., 2003).  Interestingly,  GABAA  receptor  γ2  subunit  Y
365/7F+/- 
knockin mice have been shown to have severe impairments in spatial object 
recognition that is paralleled by a specific increase in the efficacy of synaptic 
inhibition  and reduced spine density in CA3 pyramidal cells (Tretter et al., 
unpublished data). This is reminiscent of animal models of Down syndrome, in 
which  enhanced levels of hippocampal neuronal inhibition are believed to 
contribute to cognitive deficits (Fernandez et al., 2007). A recent study showed 
that fluoxetine rescued impaired neurogenesis in the dentate gyrus of Ts65Dn 
mouse model for Down syndrome; however, the authors did not determine if the 
mice had any changes in cognitive behavior (Clark et al., 2006).    171 
Together, the results presented herein suggest that the phospho-dependent 
increase in GABAA receptor functional expression may underlie the therapeutic 
action of SSRIs. However, additional experiments are necessary to further 
establish this. 
 
Future directions 
 
In this thesis, the molecular mechanisms underlying  the  phospho-dependent 
changes in the stability and function  of postsynaptic GABAA  receptor  β3 
subunits  were  described.  Furthermore,  a role for serotonergic signaling in 
modulating  β3  subunit  S408/9  phosphorylation  and  functional expression 
suggested as a possible mechanism of antidepressant action. 
 
Currently, the most widely prescribed antidepressants are SSRIs such as 
fluoxetine (Prozac
TM). However, the clinical benefit of these and other classes 
of antidepressants on the market is observed only 2-3 weeks following initiation 
of treatment, during which time  an initial increase in anxiety that has been 
linked to an increased likelihood of suicide has been reported. It would thus be 
of significant therapeutic benefit to investigate the effects of acute versus 
chronic SSRI treatment. 
 
The generation of knockin mice is a strategy often used to investigate the role of 
disease-causing mutations. The introduction of point mutations into the mouse 
genome that mimic or prevent phosphorylation at S408/9 of the GABAA   172 
receptor  β3  subunit  combined  with  biochemical,  electrophysiological  and 
behavioral studies might not only confirm the sites of kinase activity in vivo but 
also provide key insights into how prolonged changes in the efficacy of fast 
synaptic inhibition impacts behavior. Furthermore, performing these studies in 
fluoxetine-treated mice would aid in deciphering the role that these 
phosphorylation sites play in the therapeutic action of SSRIs. 
 
Elucidation of the signal transduction pathway engaged in modulation of 
GABAA  receptor phosphorylation and function following chronic 
antidepressant treatment  raises the possibility that intracellular signaling 
components could be potential targets for novel pharmacological agents with a 
faster onset of antidepressant action. 
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